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Cytosine methylation is perhaps the most dynamic and best-studied form of epigenetic 
modification. Occurring predominantly in the CG dinucleotide context within 
mammalian genomes, it is essential for normal embryonic development, X 
chromosome inactivation, genomic imprinting and transposon silencing. The 
uniqueness of CG methylation lies in its ability to be maintained following cell division 
in the absence of the signal which created it. Together, the global distribution of CG 
methylation forms an “epigenetic memory” that contributes to the differentiation and 
maintenance of distinctive somatic cell fates. Artificial manipulation of cytosine 
methylation (known as “synthetic epigenetics”) could potentially improve the creation 
and differentiation of developmentally potent cells, which will be instrumental in the 
advancement of regenerative medicine.  
I have undertaken two experimental projects investigating the potential of 
synthetic epigenetics, whereby epigenetic modifiers of non-mammalian provenance 
were overexpressed in mouse embryonic stem cells (ESCs). In plant genomes, 
methylation occurs at CHG nucleotides (where H is any base other than G) in an 
analogous manner to mammalian CG methylation, due to the action of the CMT3 
methyltransferase. Thus, in the first project, I created transgenic cell-lines with 
inducible overexpression of Arabidopsis CMT3, with the aim of creating methylation at 
CHG nucleotides. Overexpression of CMT3 was performed in three mouse embryonic 
stem cells (mESC) lines; two wild-type lines (E14 and V6.5) and a DNA methylation 
depleted line known as (DNMT-TKO). My experimental results to date suggest that 
CMT3 alone is inadequate for CHG methylation establishment in mammalian 
genomes, however, increased levels of methylation in the CG context were detected, 
suggesting it may have previously unappreciated maintenance capacity in this context.  
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The second experimental project explored the nature of DNA methylation 
removal. Cytosine methylation can be actively removed from DNA by the Ten eleven 
translocation (TET) enzymes, which oxidise 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5hmC), and further oxidised derivatives 5-formylcytosine 
(5fC) and 5-carboxylcytosine (5caC). Exactly how these analogues are returned to 
unmodified cytosine is unknown, partly because there are currently few molecular 
tools to control the transition between 5hmC, 5fC and 5caC. Unpublished in vitro 
observations suggest that Ten eleven translocation (TET) enzymes from the amœba 
Naegleria gruberi are far more effective at iteratively producing 5fC and 5caC, 
compared to mammalian homologues which produces 5hmC predominantly (T.P. 
Jurkowski, personal communication). I created mouse embryonic stem cells with 
inducible expression of Naegleria TET and mutated Naegleria TET variants, and used 
bisulphite sequencing to assess their relative ability to demethylate DNA. I found that 
the amœba TET variants were ineffective at demethylating DNA compared to 
mammalian TET controls. Unexpectedly, some constructs even showed significant 
increased methylation. I hypothesise that the Naegleria TET variants I created act as 
non-functional competitors of endogenous TET when overexpressed in mammalian 
cells. While this likely precludes their widespread use in the field of synthetic 
epigenetics, they still may provide a useful experimental tool for further study of TET 
enzyme biology.  
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1 CHAPTER 1 
INTRODUCTION & AIM 
‘EPIGENETICS’ IS A TERM that was first coined in 1942 by the developmental biologist 
Conrad Waddington, from the combination of ‘epigenesis’ and ‘genetics’ (Iwasaki & 
Paszkowski, 2014). It was originally defined as “the branch of biology which studies the 
causal interactions between genes and their products, which bring the phenotype into 
being” (Waddington, 1942). Waddington likened the role of epigenetics during 
development to an 'epigenetic landscape’, where the irreversible restrictions on the 
developmental fate of cellular lineages are like marbles rolling down separate gullies of 
a hillside (Goldberg, Allis, & Bernstein, 2007) (Figure 1.1).     
 
Figure 1.1. Waddington’s epigenetic landscape.  
In his extended metaphor, Waddington compared the accumulation of epigenetic markers during 
development to valleys on a hillside, progressively restricting developing cells (the marble) into more 
differentiated cell fates. Advancements in the understanding of epigenetics revealed that DNA 
methylation deposition during development is likely to be a key mechanism driving the formation of 
this “epigenetic landscape”. Modified from Waddington’s epigenetic landscape, reprinted from 
Waddington, 1957 
 
Decades of scientific research since Waddington has refined this relatively 
nebulous concept into a more precise definition. The current consensus amongst the 
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scientific community is that ‘epigenetics’ describes the stable (potentially life-long) 
modifications in gene expression in the absence of any alteration in DNA sequence 
(Russo, Martienssen, & Riggs, 1996). As such, it provides a mechanism for cells to 
faithfully maintain their identity and function over time without the need to alter 
genetic sequence; a concept first proven by John Gurdon with Nobel Prize winning 
nuclear transplantation experiments in the 1950s (Gurdon, Elsdale, & Fischberg, 
1958). The discovery of the molecular mechanisms behind epigenetic gene control has 
brought these concepts into reality. Chemical modification of DNA and associated 
histone proteins can result in the alteration of gene expression that can persist ad 
infinitum. For example, gene expression can be modulated at the level of chromosome 
structure; genes located within euchromatin (or “open” chromatin) are more easily 
accessed by transcription factors, thus enhancing their expression. Conversely, 
transcription factors are often blocked from accessing genes located in ‘closed’ 
heterochromatic regions, thus silencing them (Cheung & Lau, 2005; Jenuwein & Allis, 
2001). Chromatin structure and accessibility is in turn affected by modification of the 
histone proteins which associate with DNA, often featuring methylation and 
acetylation (Bannister & Kouzarides, 2011). 
Although histone modifications are undoubtedly important epigenetic 
modifications, methylation of cytosine (5-methylcytosine) is perhaps the most well-
known epigenetic modification because there is a well-described mechanism by which 
it is propagated following DNA replication (§ Section 1.1). Moreover, cytosine 
methylation is not required in naïve embryonic stem cells (the most undifferentiated 
stem cells of the body), but significantly increases during the earliest periods of cellular 
commitment, a process which is essential for the development of mammals (Okano, 
Bell, Haber, & Li, 1999). As such, DNA methylation matches the expectations of a 
developmental memory system which is congruent with Waddington’s epigenetic 
landscape.  
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1.1 DNA methylation and epigenetic memory 
Cytosine methylation was the first epigenetic modification described (Hotchkiss, 1948), 
and is still the best understood. When deposited at gene promoters, methylation is 
normally associated with the repression of genes (Deaton & Bird, 2011), although its 
presence in the gene body has been proposed to correlated with active transcription (P. 
A. Jones, 2012). DNA methylation performs various important biological functions 
such as regulation of genomic imprinting, transposon silencing, X-chromosome 
inactivation, cellular identity maintenance and the maintenance chromosomal 
integrity (Li, Beard, & Jaenisch, 1993; Riggs, 1975; Slotkin & Martienssen, 2007; G. L. 
Xu et al., 1999). It is noteworthy that DNA methylation patterns are able to exist as an 
“epigenetic memory” which can be propagated through cell-divisions (reviewed, Bird, 
2002), thus allowing developing cell lineages to 'remember' their function and identity 
even in the absence of the initial signals which created them.  
Cytosine methylation within the CG context is the most common form of DNA 
methylation in vertebrates. It is initially created by the enzymatic activity of the de 
novo methyltransferases DNMT3A and DNMT3B (Okano et al., 1999), but can persist 
through indefinite rounds of DNA replication due to the action of the maintenance 
methyltransferase, DNMT1. A critical feature of this maintenance process is the fact 
that CG dinucleotides are “symmetrical”, meaning that during DNA replication, the 
newly synthesised (unmethylated) strand can simply copy methylation status off the 
template strand  from which it was derived (Goll & Bestor, 2005) (Figure 1.2).  




Figure 1.2. Methylation maintenance at CG dinucleotides.  
The methyl (CH3) group on the cytosine bases is initially deposited by the de novo methyltransferase 
DNMT3A/3B. During cell division, hemi-methylated CG dinucleotides are recognised by the UHRF1 
enzyme, which in partnership with the maintenance methyltransferase DNMT1, propagates DNA 
methylation marks by adding a methyl group to the newly synthesised strand.  
 
Interestingly, plants possess extensive epigenetic memory at CHG sites (where 
H represents any base other than guanine), in addition to the usual CG methylation 
which is characteristic of vertebrates (Feng et al., 2010; He, Chen, & Zhu, 2011; Law & 
Jacobsen, 2010). CHG nucleotides are symmetrical in the same way as CG; cytosine 
and guanine bases exist in an identical reverse complementary sequence, regardless of 
the H base located in the centre (Figure 1.3).  
Establishment of de novo methylation at CHG sites in plants is initiated by the 
DRM1 and DRM2 methyltransferases in a process known as RNA directed DNA 
methylation (RdDM) (Goll & Bestor, 2005). Following this, a plant specific DNA 
methyltransferase known as chromomethylase 3 (CMT3) (Law & Jacobsen, 2010; 
Stroud, Greenberg, Feng, Bernatavichute, & Jacobsen, 2013), performs an analogous 
reaction to DNMT1, and restores full methylation at hemi-methylated CHG 
trinucleotides. Additional research revealed that recruitment of CMT3 to CHG contexts 
is dependent upon the histone methyltransferase KRYPTONITE (KYP/ SUVH4) 
(Jackson, Lindroth, Cao, & Jacobsen, 2002). Conversely, KYP is also recruited to 
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methylated DNA (Johnson et al., 2007), leading to the formation of CMT3/ KYP 
feedback loop which maintains CHG methylation.  However, it is not clear whether this 
interdependence is due to CMT3 interacting with KYP itself, or the histone H3 lysine 
K9 di-methylation (H3K9me2) it deposits upon chromatin (Ashapkin, Kutueva, & 
Vanyushin, 2016; Du et al., 2014; Jackson et al., 2002). 
While additional roles may be possible (Bewick et al., 2016), it has been 
hypothesised that the main function of CHG methylation in plants is silencing of plant 
specific transposons across the genome (Saze, Tsugane, Kanno, & Nishimura, 2012; 
Tompa et al., 2002). 
 
 
Figure 1.3. The methylation mechanism at the GHC trinucleotide context.  
The methylation on the cytosine is initially deposited by the DRM1/2 enzyme, the plant homologues to 
the mammalian DNMT3A/3B enzymes. These methylated CHG sites could be recognised by the KYP 
histone methyltransferase, which will deposit a H3K9me2 histone mark, leading to the recruitment of 
the CMT3 enzyme to the hemi-methylated CHG trinucleotide, and remethylate the newly synthesised 
strand from the opposite direction. 
 
1.1.1.1 The lifecycle of DNA methylation in mammals 
Epigenetic memory in the form of CG methylation is characterised by 
consistently high levels in the somatic tissues of mammals, yet dramatic remodelling in 
the germline.  
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CG methylation levels are between 70% and 85% in a wide-range of mouse 
tissue tested thus far (Hon et al., 2013). Given that cells within these somatic tissues 
are generally dedicated to a specialised function, it is perhaps not surprising that they 
are encumbered by high levels of epigenetic memory in the form of CG methylation. 
Indeed, the only time low CG methylation has been observed in somatic cells is under 
pathological situations such as cancer, and is associated with a dramatic loss of cellular 
functionality (Feinberg & Vogelstein, 1983; Ziller et al., 2013).  
In contrast to somatic cells, methylation in the germline rises and falls in 
synchrony with major developmental checkpoints (Figure 1.4). Sperm possess much 
more methylation than oöcytes (90% and 40% respectively) (Kobayashi et al., 2012; 
Seisenberger et al., 2013), however, sperm derived methylation is rapidly removed in 
male pronucleus immediately following fertilisation (Migicovsky & Kovalchuk, 2011; 
Teng & Zhou, 2013) (Figure 1.4). Thus, CG methylation levels start at relatively low 
levels in the zygote and early embryo, and accumulate as cells progressively become 
committed to distinct developmental trajectories (reviewed, Lee, Hore, & Reik, 2014; 
Reik, Dean, & Walter, 2001). Around the time of mouse implantation, methylation of 
the genome occurs de novo through the action of the DNA methyltransferases 
DNMT3A and DNMT3B (Kafri et al., 1992) (Figure 1.4).  
Interestingly, it is also around this time that naïve stem cells lose their 
developmental capacity and commit to a restricted cellular fate. Naïve embryonic stem 
cells, both in vivo (Z. D. Smith et al., 2012) and in vitro (Ficz et al., 2013), display 
around 20-30% CG methylation genome-wide, whereas the post-implantation embryo 
and stem cells derived from it, known as epiblast stem cells, possess a significantly 
higher (70-85%) CG methylation level (Hon et al., 2013). As such, there is an inverse 
relationship between the developmental potency of early stem cells and the 
methylation level in their genome (Lee et al., 2014). Once DNA methylation is 
established in early post-implantation development, DNMT3A and DNMT3B become 
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down-regulated and generally stay low in the differentiated adult somatic tissues 
(Okano et al., 1999), with high DNA methylation being maintained by DNMT1.  
In mammals, the germline is not a continuous cellular lineage, but is instead 
reprogrammed from somatic tissue (Nieuwkoop & Sutasurya, 1979). This process 
occurs during definition of the primordial germ cells (PGCs) from the epiblast. 
Coincident with primordial germ cell definition is a dramatic demethylation event in 
which 95% of CG methylation is removed (Seisenberger et al., 2012). Demethylation in 
primordial germ cells is largely passive, viz., the global loss of DNA methylation is 
induced by the disruption of the methylation maintenance system (Ohno et al., 2013; 
Z. D. Smith & Meissner, 2013). Methylation is then re-established asymmetrically 
during oögenesis and spermatogenesis (Kagiwada, Kurimoto, Hirota, Yamaji, & Saitou, 
2013; Seisenberger et al., 2012). In the male germline, DNA methylation is laid down 
within days after the primordial germ cells have arrived in the gonad. In contrast, re-
methylation in the female germline is only completed during the final stages of oöcyte 
development prior to ovulation (Hill, Amouroux, & Hajkova, 2014), and completion of 
the lifecycle at fertilisation.  
 
  




Figure 1.4. Graphical representation of epigenetic reprogramming during mammalian life cycle.  
Once specified, primordial germ cells undergo a wave of massive DNA demethylation, leading to the 
erasure of parental methylation patterns, including that of the imprinting regions. As the sex of the 
embryo become determined, primordial germ cells will become remethylated through de novo 
methylation by DNMT3A/3B. It is noteworthy that remethylation during gametogenesis occurs 
asymmetrically, resulting in spermatozoa obtaining 90% methylation at their CG context, whilst 
oöcytes are only around 40% methylated at their CG context. Shortly after fertilisation, both maternal 
and paternal pronuclei will undergone demethylation, although this process is active and occurring 
more rapidly in the paternal pronucleus. The demethylation will persist until around implantation when 
a second wave of de novo methylation occurs, differentiating the embryonic stem cells into the 
distinctive somatic cell fates. 
1.1.1.2  Bisulphite sequencing and the assessment of epigenetic memory 
Understanding the establishment and removal of epigenetic memory during the 
mammalian lifecycle has been greatly stimulated by development of genome-wide 
bisulphite sequencing. Classical, locus specific bisulphite sequencing methods were 
first developed in the early 1990s (Frommer et al., 1992). These methods relied upon 
the ability of the bisulphite molecule to convert cytosine into uracil (U) by 
deamination, but inability to deaminate methylated cytosine (5mC) (Figure 1.5). 
Recent combination of bisulphite treatment of DNA with high-throughput sequencing 
has allowed accurate, genome-wide quantitation of DNA methylation down to single 
base pair levels (Lister & Ecker, 2009). This means that ‘memory-capable’ methylation 
at CG dinucleotides (and in the case of plants, CHG trinucleotides) can be 
distinguished from background non-memory capable methylation. Recently, the 
invention and the optimisation of an alternative sequencing strategy known as post-
bisulphite adaptor tagging (PBAT) (Miura, Enomoto, Dairiki, & Ito, 2012; Peat et al., 
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2014), has significantly improved the efficiency of bisulphite library construction, 
allowing low-cell number samples to be accurately quantified. 
 
Figure 1.5. Bisulphite conversion of cytosine bases.  
Unmethylated cytosine bases are first converted into uracil through bisulphite treatment, which is then 
converted into thymine during PCR. On the other hand, the methylated cytosine bases are protected 
from bisulphite conversion and remains unaltered during bisulphite sequencing. By comparing the 
bisulphite treated bases to reference sequences, it be possible to recognise DNA methylation down to 
single base pair resolution. 
 
1.1.2 TET Protein Family and active DNA demethylation 
It has long been suspected that passive demethylation does not account for all the 
demethylation activities which occur during mammalian epigenome reprogramming. 
Indeed, the observation that zygotic male pronuclei undergo dramatic DNA 
demethylation independently of cell division (Mayer, Niveleau, Walter, Fundele, & 
Haaf, 2000; Park, Jeong, Shin, Lee, & Kang, 2007; Santos et al., 2013) strongly 
supports this proposition. Recently it was discovered that the ten eleven translocation 
(TET) protein family are responsible for active demethylation in certain developmental 
contexts (Iyer, Tahiliani, Rao, & Aravind, 2009; Tahiliani et al., 2009). For example, 
TET knockdown in embryonic stem cells reduces the expression of pluripotency genes 
and increases methylation at their promoters (Ficz et al., 2011; Williams et al., 2011). 
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Although apparently not required for the maintenance of pluripotency, TET proteins 
are essential for reprogramming differentiated cells to the pluripotent state (Dawlaty et 
al., 2014; Hu et al., 2014). TET3 is highly expressed in oöcytes, and the removal of it in 
these cells significantly impairs DNA demethylation in the zygote post-fertilisation 
(Peat et al., 2014). TET1 appears to be pivotal for reprogramming of imprint control 
regions (Piccolo et al., 2013), whereas TET2 plays a central role in mediating 
differentiation of hæmatopoietic stem cells, as well as contributing to pluripotency (Ko 
et al., 2011).  
TET proteins initiate DNA demethylation by catalysing the conversion of 5-
methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and further oxidised 
derivatives, 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), a process reliant on 
an intact Fe2+ and oxoglutarate dependent catalytic site (S. Ito et al., 2011). There are 
several ways in which these oxidation reactions can give rise to DNA demethylation. 
The first is that 5hmC is not recognised by the UHRF1/NP95 complex, effectively 
disengaging maintenance methylation at affected sites (Valinluck & Sowers, 2007). 
Secondly, DNA base excision repair proteins such as thymine-DNA glycosylase (TDG) 
can deaminate oxidised cytosine and ultimately cause excision of 5fC and 5caC (Y. F. 
He et al., 2011; Hu et al., 2014; Kohli & Zhang, 2013). As yet, it is not known which of 
the three oxidised cytosine variants (i.e. 5hmC, 5fC or 5caC) is the most important for 
DNA demethylation, partly because there are very few tools available to manipulate 
TET oxidative extent.  
1.1.2.1 Naegleria TET as an experimental tool to study DNA demethylation  
The TET orthologue from the amœboflagellate Naegleria gruberi may provide a tool 
from which to study oxidative DNA demethylation. Whereas mammalian TET usually 
stops oxidation at 5hmC and produces only small amounts of 5fC and 5caC, Naegleria 
TET efficiently converts 5mC into 5fC and 5caC, and only transiently produces 5hmC 
(Jurkowski T.P., personal communication). Thus, overexpression of Naegleria TET in 
a mammalian cell may augment methylation removal across the mammalian genome, 
CREATING A NEW CODE CHAPTER 1 | INTRODUCTION & AIM 
11 
 
and potentially enhancing the efficiency in which somatic cell lines can be 
reprogrammed. 
The ability of Naegleria TET to continue oxidation to 5caC lies in the unique 
structure of its active site. Specifically, it contains a large “hydrophobic pocket” that 
allows rotation of the C-C bond from which the hydroxymethyl group is attached to the 
cytosine ring, allowing iterative oxidation to occur in situ (Hashimoto et al., 2015). This 
hydrophobic pocket is formed through the positioning of three amino acids; of alanine 
from position 212 (A212), valine from position 293 (V293) and phenylalanine from 
position 295 (F295). It has been shown that mutations of the A212 amino acid into 
specific amino acids reduces the size of the hydrophobic pocket, abolishing its ability to 
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1.2 Manipulating the epigenome 
1.2.1 Global epigenetic memory removal  
Historically, the relationship between DNA hypomethylation and developmental 
potency has only been described in correlative terms. However, recent experiments 
have shown that removal of DNA methylation can drive pluripotency, implying some 
degree of causality. For example, inhibition of DNMT1 either through RNA 
interference (RNAi), or 5-azacytidine, dramatically enhances the rate at which induced 
pluripotent stem cells (iPSCs) can be created (Mikkelsen et al., 2007; Theunissen et al., 
2011).  
The link between DNA demethylation and the naïve pluripotent state is further 
strengthened by recent discoveries involving cultured stem cells. Two small-molecule 
inhibitors of the FGF and GSK3B signalling pathway (known as 2i for short) cause 
classically grown mouse embryonic stem cells to undergo a dramatic demethylation 
process (Ficz et al., 2013; Habibi et al., 2013; Leitch et al., 2013), thus matching in vivo 
naïve stem cell methylation levels. The mechanism by which demethylation occurs in 
naïve embryonic stem cells also likely involves inhibition of DNA methyltransferases. 
Following 2i treatment, both DNMT3A and DNMT3B mRNA are dramatically reduced 
(Ficz et al., 2013), and UHRF1/Np95 appears to be actively excluded from the nucleus 
(von Meyenn et al., 2016). Importantly, these hypomethylated embryonic stem cells in 
2i media conditions show enhanced developmental potency compared to classical 
culturing techniques and have allowed derivation of germline competent cells in 
divergent mouse strains, rats and primates for the first time (reviewed, Martello & 
Smith, 2014). As such, they may well form a cornerstone resource for regenerative 
medicine. 
 In addition to repression of DNA methyltransferases (resulting in passive DNA 
demethylation), it appears that active removal of DNA methylation can also stimulate 
developmental potency. Overexpression of TET proteins increases the production of 
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induced pluripotent stem cells in a manner which is dependent upon their catalytic 
activity (Costa et al., 2013; Doege et al., 2012; Gao et al., 2013), thus implicating its 
demethylating effects. An alternative hypothesis is that TET enhances pluripotency by 
producing 5hmC, rather than stimulating DNA demethylation per se. However, this 
has not been tested because there are few ways to distinguish between TET-enhanced 
demethylation and 5hmC production. Moreover, most induced pluripotent stem cell 
reprogramming protocols are complicated and difficult.  
1.2.2 Targeted Epigenome Editing  
In recent years, epigenome manipulations have been undertaken at specific loci with 
the intention of silencing or activating specific genes. In particular, much focus has 
been on silencing oncogene expression with a view to slowing or halting tumorigenesis 
(Stolzenburg et al., 2015; Tuesta & Zhang, 2014). Recent research has revealed that 
modulation of gene expression through site-specific DNA methylation is indeed 
possible, which could be achieved through generation of dCas9-DNMT3A fusion 
protein, allowing targeted deposition of epigenetic modifiers at gene promoters (Liu et 
al., 2016; Vojta et al., 2016). More astonishingly, it has also been demonstrated that 
targeted DNA demethylation could be carried out in vivo, through lentiviral delivery of 
dCas9-TET1 vector (Liu et al., 2016). 
 Targeted activation of gene expression may also have useful biomedical 
applications. For example, it has been proposed that sickle cell anæmia and β-
thalassæmia could be ameliorated through the activation of developmentally repressed 
γ-globin to compensate for the loss of β-globin functions (Gräslund, Li, Magnenat, 
Popkov, & Barbas, 2005), targeted alteration of DNA methylation could provide an 
alternative method by which γ-globin could be activated.  
Until now, both global and targeted epigenomic manipulations have focused 
upon the alteration of existing epigenetic systems, using epigenetic modifiers which are 
largely derived from species of interest. Nevertheless, a new frontier of the synthetic 
epigenetics field is the use of epigenetic modifiers from divergent metazoan species, 
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and eventually, creation of a completely novel system of epigenetic memory in the 
genome. If achievable, it could usher a new age in which the epigenome of an organism 
could be edited in a similar fashion as their coding sequence, potentially transforming 
medical treatments and biotechnological research.  
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1.3 Research Aims 
In an attempt to explore the potential of synthetic epigenetics in this research project, I 
attempted to (1) create and (2) erase, epigenetic memory in a mammalian cell:  
1: Establishment of the synthetic epigenetic memory 
In this experiment, I attempted to create a novel system of epigenetic memory in 
mammalian cells using a top-down epigenetic editing approach. To do this, I 
overexpressed the plant-specific CMT3 methyltransferase in E14 and V6.5 mouse 
embryonic stem cell and DNMT triple knockout (TKO) lines (Figure 1.6).  
 
Figure 1.6. Synthetic CHG methylation creation research concept.  
The current research attempts to introduce synthetic CHG trinucleotide methylation across the 
mammalian genome through the integration of plant based methyltransferase CMT3 into the genome 
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2: Epigenetic memory erasure and the role of 5hmC  
In my second major experiment, I attempted to test if Naegleria TET’s superior 
demethylation activity in vitro could be replicated within a mammalian cell. To do this, 
I overexpressed Naegleria TET (nTET) in mouse embryonic stem cells and compared 
it to mutant nTET sequences (altered to favour the production of 5hmC as opposed to 
5fC or 5caC) and mammalian TET as a control (Figure 1.7). Additionally, I attempted to 
examine TNGA’s suitability as a site-specific methylation reporter system through the 
overexpression of murine TET1 catalytic domain (mTET1-CD). 
 
Figure 1.7. TET transfection experiment concept.  
Mouse embryonic stem cells were transfected with either mammalian TET1, Naegleria TET or mutant 
Naegleria TET enzymes. Mammalian TET1 is relatively inefficient in completing the demethylation 
process in vitro, and produces relatively more 5hmC compared to 5fC and 5caC. In contrast, Naegleria 
TET is much more active and iteratively oxidises 5mC right through to 5caC with high efficiency 
(Jurkowski T.P., unpublished observations). Naegleria TET mutants were also created where the 
oxidation reaction has been “forced” terminate at the 5hmC. 
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2 CHAPTER 2 
MATERIAL & METHODS 
2.1 Primer Design and storage 
Primers for both PCR and Sanger sequencing were designed using the website 
Primer3Web (http://primer3plus.com/web3.0.0/primer3webinput.htm). Poly-
nucleotide repeats of 3 or more base-pairs were excluded, as were primers with more 
than three C or G nucleotides in the 3’ region. Annealing temperature was designed to 
be between 58-64°C and differences in annealing temperature between primer pairs 
set to be less than 2°C. Optimum primer size was set to be between 22-24 bp long. 
Primer sequences used to amplify DNMT3A/3B sequences are presented in the 
following table: 







Primer sequences used to amplify CMT3 gene sequence are presented in the following 
table: 











Primer sequences used to amplify the TET1 variant sequences are presented in the 
following table: 
Table 2.3. Primers used for TET variant sequence amplification. 




Lyophilised oligos were diluted in TE buffer to form a 200 mM storage stock, and 
was stored in -20°C freezer. The storage stock is further diluted in 1/10 ratio in Milli-Q 
water to form 20 mM primer working stock.  
 
2.2 Bacterial Transformation and Cloning 
Genes of interest were cloned using Subcloning Efficiency™ or Library Efficiency 
DH5α™ Competent Escherichia coli cells (Thermo Fisher), using manufacturer’s 
protocol (Figure 2.1). Briefly, competent cells were first thawed on ice after they have 
been taken out of freezer and 1 μL (containing 1-10 ng) of vector was added to the cell 
culture and mixed gently. The cell culture was than incubated on ice for 30 minutes. 
Upon thawing, bacteria were heat-shocked by incubating them for 45 seconds at 42°C 
on PCR machine (Kyratec, SuperCycler), encouraging uptake of vectors. Transformed 
bacteria were then incubated on ice for 2 minutes after heat shock treatment before 
being transferred into Falcon™ 14 mL Round-Bottom Polypropylene Tubes with 950 
μL of Super Optimal Broth (S.O.C.) Medium (Thermo Fisher, cat. 15544034). The 
tubes were incubated at 37°C on 225 rpm for an hour (Thermo Scientific Forma 420 
CREATING A NEW CODE CHAPTER 2 | MATERIAL & METHODS 
19 
 
Shaking Orbital Incubator), after which the media were pour onto an agar plate 
containing Luria Agar (Supplementary table 1) infused with 0.1% of the appropriate 
antibiotics and incubated overnight at 37°C. 
 After overnight incubation, colonies with well-defined boundaries were picked 
using pipette tips and transferred into 14 mL round-bottom tubes containing 7 mL of 
Luria Broth infused with 0.1% of the appropriate antibiotics. The tubes were incubated 
for 24 hours at 37°C at 225 rpm (Forma 420 Orbital Shaker). At the end of incubation 
period, bacteria were spun down at 4600 rpm for 5 minutes (Thermo Scientific™ 
Heraeus Multifuge 3SR+), and supernatant was removed. Vectors were isolated from 
bacteria using Wizard® Plus SV Minipreps DNA Purification System, following 
manufacturer’s instruction.  
Bacterial strains used were preserved long-term by suspension in glycerol 
(Sigma, G5516-1L) at 2:1 ratio (400 μL of bacteria sample to 200 μL of glycerol) in a 1.5 










Figure 2.1. Bacterial vector cloning strategy. 
 During bacterial vector cloning, the gene-of-interest (contained within a vector with antibiotics resistance) was first introduced and integrated into bacterial genome 
through heat-shock treatment. Transformed bacteria were selected form through antibiotics treatment, which kills any untransfected bacterium that does not contain 
resistance gene. Transformed bacteria were then allowed to multiply in number, and the plasmid-of-interest harvested through DNA purification. 
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2.3 DNA Sequencing  
Cloned insert identity was assessed by Sanger sequencing using the Genetic Analysis 
Service (GAS) at University of Otago. For plasmid sequencing, 150 ng of vector was 
added with 1.6 μL of 20 mM primer and Milli-Q water was added until reaction mix 
reached 5 μL in volume. 
The data obtained from GAS was processed and analysed using Sequencher 
software. Regions of low sequencing quality were trimmed and contigs were assembled 
from various extension sequences and a reference sequence for analysis on mutations 
(mismatches between sequence obtained and the reference sequence), and their effects 
on amino acid sequence. Nucleotide sequences obtained were translated into amino 
acid sequence using online tools (http://www.ebi.ac.uk/Tools/st/emboss_transeq/). 
Amino sequence alterations in nTET mutants were compared and confirmed using 
multiple sequencing alignment tool “MUSCLE” (Multiple Sequence Comparison by 
Log-Expectation), under the parameter ClustalW (with colour). 
 
2.4 BP Recombination 
Genes-of-interest were shuttled into the Gateway® pDONR221 vector through a 
process known as BP recombination (Figure 2.2). BP recombination were performed in 
a PCR tube containing 10 μL of reaction mix (Table 2.4), and incubated overnight at 
25°C. Upon the end of the incubation period, recombination reaction was terminated 
through addition of 1 μL of Thermo Scientific Proteinase K enzyme (AM2548), reaction 
mix was then incubated at 37°C for 10 minutes. BP recombination was unnecessary for 
the Arabidopsis lyrata CMT3 transgenes, as they were ordered as pre-cloned 
pDONR221-CMT3 vector (GenScript, OAa24945). 
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Table 2.4. BP recombination reaction mix formula. 
Reagent Volume 
PCR product 1-7 μL 
Gateway® pDONR221 vector 1 μL 
TE Buffer Add till reaction mix reach 10 μL 
Gateway® BP Clonase™ II Enzyme Mix 2 μL 
Total 10 μL 
 
 
2.5 LR recombination 
Genes-of-interest were shuttled from the donor to the entry vector using LR 
recombination (Figure 2.2). LR recombination was performed in a PCR tube 
containing 10 μL of LR recombination reaction mix (Table 2.5) and incubated 
overnight at 37°C. The LR recombination reaction was then terminated through the 
addition of 1 μL of Thermo Scientific Proteinase K enzyme, reaction mix was then 
incubated at 37°C for 10 minutes. 
 
Table 2.5. LR recombination reaction mix formula. 
Reagent Volume 
Entry vector 150 ng 
pTAG-Cherry vector 150 ng 
TE Buffer Add till reaction mix reach 10 μL 
Gateway® LR Clonase™ II Enzyme Mix 2 μL 
Total 10 μL 
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To screen correct inserts within the destination vector (irrespective of their sequence) 
primers capable of amplifying from the LR recombination sites were designed: 
 









2.6 PiggyBac Inducible Vector System (pB-tetO2-mCherry) 
Genes-of-interest were shuttled into the pB-tetO2-mCherry expression vector (Hore 
T.A., unpublished). This vector features a PiggyBac transposon, Gateway 
recombination sites and an inducible promoter from the tetracycline inducible (Tet-
On) system (Supplementary figure 2). In order to activate expression from this 
promoter, co-transfection of a second PiggyBac plasmid (pB-CAG-rtTA-Puro) is 
necessary. The pB-CAG-rtTA-Puro contains the reverse tetracycline-controlled 
tansactivator (rtTA) protein, which is only able to bind to the TetO sequences and 
initiate gene expression in the presence of Tetracycline, or analogues such as 
Doxycycline (DOX), as used in this study (Gossen, Bender, Muller, & Freundlieb, 
1995). A third PiggyBac (pCAG-pBASE) plasmid was also co-transfected with the 
expression vector, the pCAG-pBASE vector contains a PiggyBac transposase that can 
aid the integration of the gene-of-interest into the host genome through a “cut and 
paste” mechanism (Chen et al., 2015). 
A special feature of pB-tetO2-mCherry is an internal ribosomal entry site 
(IRES) immediately downstream of the gene interest, and following that, a fluorescent 
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reporter protein mCherry. This means that any cell expressing the gene of interest is 
labelled by fluorescence and can thus be isolated from co-cultured control cells using 
fluorescence activated cell sorting (FACS).  
 
2.7 PiggyBac Constitutive Vector System (pB-DEST-HYG) 
To establish cell lines with stable and constitutive transgene expression (such as the 
case of CMT3 transfection into DNMT-TKO cell line), the genes-of-interest was 
shuttled into the pB-DEST-HYG expression vector (Supplementary figure 3). This 
vector contains a PiggyBac transposon, Gateway recombination sites, hygromycin 
resistance gene and a constitutive promoter (CAG) known as cytomegalovirus 
immediate-early (CMV IE) promoter. The use of CMV IE promoter in this vector allows 
for a strong and constitutive transgene expression in transfected cells (Wilkinson & 
Akrigg, 1992). This expression vector also relies on the activities of PiggyBac 
transposase for integration into host genome (Chen et al., 2015). The pB-DEST-HYG-
CMT3 vector also contains a hygromycin B phosphotransferase (hph) gene, which 
confers hygromycin resistance to transfected cells (Gritz & Davies, 1983), permitting 
their survival during antibiotic selection. This allows a homogenous transfected cell 
culture to be established following antibiotic selection. 















Figure 2.2. Graphical representation of Gateway™ cloning system and PiggyBac transposon integration.  
The gene of interest is first shuttled into the Donor Vector through BP recombination to form the Entry  Vector. The gene-of-interest was then shuttled from the Entry 
Vector into the Destination Vector to form the Expression Vector, which can then be intergrated into host cell genome with the aid of the PiggyBac transposase 
containing suicide vector, pCAG-pBASE. 
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2.8 Polymerase Chain Reaction 
Sequences-of-interest were amplified using the polymerase Phusion® High-Fidelity 
(HF) DNA Polymerase (NEB, M0530L), following manufacturer’s recommendations 
and the reaction mix listed in Table 2.7. Thermal cycling was carried out using “Satt63” 
program, (98°C, 2 min; 32 × (98°C, 10 secs; 63°C, 10 secs; 72°C, 20 secs)). 
Table 2.7. PCR reaction mix formula. 
Reagent Concentration Volume 
Phusion® HF Buffer 1x 2 μL 
dNTPs 200 μM each 0.4 μL 
Forward Primer 0.5 μM 0.25 μL 
Reverse Primer 0.5 μM 0.25 μL 
Template DNA (mESC cDNA) - 0.2 μL 
Phusion® HF DNA polymerase 0.02 unit/ μL 0.1 μL 
Molecular Water (H2O) 50x 6.8 μL 
Total - 10 μL 
 
To identify optimum temperature for nTET amplification, the “SattGRAD61-
72LONG” program was used, whereby DNA extension times were lengthened to 1 
minute and the annealing temperature varied across the PCR block from 61°C at the 
leftmost column to 72°C at the rightmost column. 
 
2.9 Confirmation of cloning 
Colony PCR was performed in order to screen many potential clones for the gene of 
interest without having to purify DNA first. Picked colonies were diluted with 100 μL of 
TE buffer solution, from which 0.5 μL was taken and combined with 9.8 μL of PCR 
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reaction mix and amplified as usual, except with an initial 10-minute incubation at 
98°C, allowing lysis of cells to expose DNA content for amplification.  
For situations where colony PCR was not appropriate, presence of the gene-of-
interest in expression or destination vector were screened by restriction digest as 
outlined in Table 2.8. 
 
Table 2.8. Restriction digest reaction mix formula. 
Reagent Volume 
FastDigest™ Green Buffer (10x) (B72) 2 μL 
Restriction enzymes 0.5 μL 
Vectors 1 μL 
H2O 16.5 μL 
Total 20 μL 
 
 
2.10 Gel electrophoresis and extraction 
DNA fragment size were determined using gel electrophoresis. Agarose gels used for 
gel electrophoresis were made at 1% concentration w/v in Tris/ Acetate/ EDTA (TAE) 
buffer solution. Biotium GelRed™ was added at 1/20,000 concentration to the agarose 
mixture, allowing visualisation of DNA fragments under ultraviolet light. Restriction 
digestion reaction mix were loaded onto the wells along with DNA ladders and ran at 
110V for 60 minutes.  DNA fragments on the gel were visualised and photographed 
using a UV light transilluminator. 
For agarose gels that were used in gel extraction experiments, SYBR® Safe DNA 
gel stain was added at 1/ 10,000 concentration to agarose gel. Extraction of DNA 
fragments was performed under Midi LED Transilluminator, which could visualise 
SYBR® Safe DNA gel stain. Once DNA fragments were visualised, gel slices were 
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excised and DNA were extracted in accordance with the QIAquick Gel Extraction Kit 
protocol (Qiagen, cat.  28704). DNA fragments were collected in 30 μL of molecular 
water and concentration of samples obtained were measured using NanoDrop 2000c 
Spectrophotometer.   
 
2.11 Mouse embryonic stem cells 
Wild-type mouse embryonic cell lines used during the current experiment includes E14 
and V6.5 lines. E14 cells were originally derived from a blastocyst of strain 129/Ola 
mice (Hooper, Hardy, Handyside, Hunter, & Monk, 1987; A. G. Smith & Hooper, 
1987). While V6.5 cells were derived from inner cell mass of a mouse embryo from 
C57BL/6 x 129/sv cross (Rideout et al., 2000; Simhadri et al., 2014). DNMT-triple 
knockout (TKO) cell lines used during synthetic methylation creation experiment 
originates from a DNMT1 knockout line of the DNMT3A-/- DNMT3B -/- cell line and are 
deprived of any methyltransferase activity, this cell line is blasticidin, puromycin and 
hygromycin resistant (Okano et al., 1999; Tsumura et al., 2006). Targeted Nanog GFP, 
clone A (TNGA) cell line used during the site-specific methylation reporter system 
experiment contains an eGFP reporter sequence inserted at AUG codon of the Nanog 
gene, allowing GFP protein to be co-expressed with Nanog (Chambers et al., 2007). 
Mouse embryonic stem cells were cultured in Embryonic Stem cell Media with 0.1% 
Leukæmia Inhibitory Factor (ESM+LIF) (Supplementary table 3 for ESM formula) on 
Corning® Culture Dishes coated with 0.1% gelatin (Gelatin from porcine skin, Sigma, 
G1890-1KG). Cell cultures were incubated in humidified atmosphere at 37 °C with 5% 
CO2.  
 
2.12 Cell Passage 
Cell cultures were passaged every 2 to 3 days to prevent overcrowding and to maintain 
cell cultures at peak condition for further experimentations. During cell passage, 
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medium was removed through aspiration and cell culture was washed with PBS to 
remove any residual media. StemPro® Accutase® (Thermo Fisher Scientific, A11105-
01) were added to dissociate cell colonies from culturing plate according to volumes 
given in Supplementary table 4. Cells were incubated at 37°C for 3 minutes, allowing 
colonies to become fully dissociated. Dissociated cells were transferred into a 14 mL 
Falcon™ tube containing 10 mL of PBS solution. Cells were pelleted by a 3-minute spin 
at 10 RCF (Hettich Rotofix 32A Centrifuge), supernatants were aspirated. Cell pellets 
were resuspended in Embryonic Stem Cell Media + LIF (ESM+LIF) and transferred 
onto new culturing plates. Cell cultures were typically split in 1:6 or 1:8 ratios. 
 
2.13 Cell Freezing  
Cell cultures were regularly frozen down to reserve them for later experimentations. 
Briefly, cells were harvested following the protocol given in the Cell Passage section (§ 
Section 2.12) and counted using Neubauer Chamber (Celeromics), following 
manufacturers protocol. Following a further centrifugation step, pellets were 
resuspended in 250 μL of Freezing Media (N2B27 Media base; 15% FBS; 10% DMSO), 
at the ratio of 4 million cells/ mL of media and transferred into Corning™ 1 mL 
Cryogenic Storage Vials. Cell cultures were then frozen down in CoolCell® Cell Freezing 
Container according to manufacturer’s protocol (Yokoyama, Thompson, & Ehrhardt, 
2012), and stored in -80°C freezer.  
 
2.14 Cell Transfection 
Cell cultures were harvested in accordance with protocol given in the Cell Passage 
section (§ Section 2.12) of which 1 million was transferred into one well of a six-well 
plate containing 250 μL of Opti-MEM® Reduced Serum Media (Thermo Fisher 
Scientific, cat. 31985062). Construct mixes (Table 2.9) were prepared by pipetting 
4,000 ng of various vectors into a single PCR tube. Opti-MEM® media was added to 
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construct mix, increasing total volume to 125 μL (Table 2.9), and the reaction mix was 
then incubated for 5 minutes. 
 FuGENE® HD Transfection Reagent (Promega, E2311) was prepared separately 
by adding 89 μL of Opti-MEM® to 36 μL of FuGENE® HD (Table 2.9) then incubating 
the solution for 5 minutes. Once construct mix and FuGENE® solutions were incubated 
separately for 5 minutes, they were added together and incubated for an additional 20 
minutes before being added drop-wise to individual cell cultures. Cell cultures were 
then incubated at 37°C for 2 to 6 hours in 250 μL of media allowing transfection to take 
place.  
After the initial incubation period, 5 mL of ESM was added and cell cultures 
were incubated for an additional 24 hours, at which point an appropriate antibiotic 
was added. This lead to significant cell death initially, therefore medium was changed 
daily to remove dead cells and new antibiotic was added with each replacement 
medium. Transfection was considered complete once cell death has subsided. Control 
transfections were performed, whereby no plasmids were added to the cells, allowing 
determination of antibiotic effectiveness.  
Once stable cell lines were created, induction of gene expression (and the 
relevant reporter) was performed by adding 2 ug/mL doxycycline (DOX) for 48 hours 
to induce transgene expression (Figure 2.3). 
 














4,000ng 4,000ng 4,000ng To 125 μL 36 μL 89 μL 
Negative control - - - 125 μL - 125 μL 
 




Figure 2.3. Graphical representation of mouse embryonic stem cell transfection strategy.  
Mouse embryonic stem cell were transfected through addition of a destination vector, transfection 
reagent and transposase containing vector known as pBASE. Once transfected, the cell culture was 
given a 24-hour recovery period, cells that have been successfully transfected were selected for 
through antibiotics selection. Once a stable cell line was established, transgene expression was 
induced through a 48-hour DOX treatment regime.   
 
2.15 Total Nucleic Acid Extraction 
DNA and RNA from transfected cells were extracted for further analysis through total 
nucleic acid (TNA) extraction technique which relies on a magnetic bead purification 
technique. Cells were homogenised by resuspension in a guanidinium thiocyanate 
(GITC) lysis buffer. 60 μL of lysate was added to 40 μL of Tris-EDTA (TE) diluted 
magnetic beads (GE Healthcare, GEHE45152105050250) and the solution was mixed 4 
to 6 times until homogenised. 80 μL of isopropanol was added and the solution was 
incubated for a minute allowing precipitation of the nucleic acids.  
 PCR tubes were placed on a magnetic rack for 5 minutes, allowing nucleic acid 
bounded to beads to collect on the wall of PCR tubes. Supernatant was then removed 
and the beads were washed twice with 150 μL of wash buffer (2 parts TE: 3 parts GITC: 
4 parts isopropanol). The beads were then further washed with 150 μL of isopropanol 
to remove GITC, then washed twice with 200 μL of freshly prepared 70% ethanol to 
remove isopropanol. 70% ethanol was removed and the beads were air-dried for 5 
minutes. Once sufficiently dried, nucleic acids were eluted from magnetic beads 
CREATING A NEW CODE CHAPTER 2 | MATERIAL & METHODS 
32 
 
through resuspension in 50 μL of molecular water. Nucleic acid concentration was 
measured with NanoDrop 2000c spectrophotometer.  
 
2.16 Fluorescence Activated Cell Analysis & Sorting 
Transfected cells were initially analysed for mCherry (and GFP) reporter gene 
expression using flow cytometry by BD LSRFortessa™, with cell pellet being prepared 
in 500 μL of FACS Buffer (PBS base; 5% FBS & 0.01% DAPI) solution. During FAC 
analysis, 10,000 events (cells) were recorded and analysed from each experimental 
group.  
A BP Aria D Bioscience cell sorter was used to collect transfected cells 
according to mCherry expression status. Cells were initially gated based on four 
properties; FSC-A vs. SSC-A, FSC-H vs. FSC-A, DAPI expression and mCherry 
expression. Forwards scatter area (FSC-A) versus side scatter area (SSC-A) was used to 
select on cell size and morphology, with outliers likely to be cellular debris.  Forward 
scatter height (FSC-H) versus forward scatter area (FSC-A) selected for single cells, as 
cells with an abnormally high FSC-A vs. FSC-H are likely to be doublets (two cells in a 
single droplet) and excluded from further analyses. 4;6-diamino-2-phenylindole 
(DAPI) staining permit selection for viable cells (Kim, Yan, Lee, Sgagias, & Cowan, 
2004), as DAPI only stains chromosomes of dead cells due to their compromised 
membrane integrity, therefore DAPI-positive cells were excluded from further analysis. 
Cells were collected in 96-well plates containing 120 μL of GITC buffer solution, 
allowing cells to be lysed during collection. 
 
2.17 Post-Bisulphite Adaptor Tagging 
During the current experiment, DNA extracted were treated with Post-bisulphite 
Adaptor Tagging (PBAT),  a form of genome-wide bisulphite sequencing that is both 
convenient and able to deal with limited cell numbers (Miura et al., 2012) (Figure 2.4). 
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The major difference between PBAT and conventional whole-genome bisulphite 
sequencing (WGBS) method is that addition of Illumina sequencing adapters occurs 
after bisulphite treatment, thus minimising DNA degradation of prepared libraries. 
During PBAT, 24 μL of purified DNA from each sample was then subjected to 
bisulphite conversion and purification using the Imprint® DNA Modification Kit 
(Sigma-Aldrich, MOD50) according to protocol supplied. 
 Following bisulphite conversion, 4 μL of First Strand Synthesis Reaction Mix 
(Table 2.10) was added to 20 μL of bisulphite treated DNA for first strand synthesis 
and forward adaptor tagging. Forward primer BioP5N7 was used, which contains 
biotin, P5N7 adaptor sequence and a 7 bp randomly generated oligonucleotide 
sequence. Reaction mix were first incubated at 65°C for 5 minutes then at 4°C while 1 
μL of Klenow Fragment (3’-5’ exo-) (NEB, M0212L) was added to the reaction mix. 
Once DNA polymerase was added, incubation was resumed with incubation 
temperature gradually increasing from 4°C to 37°C at 6°C per minute, once at 37°C, the 
reaction mix were then further incubated for 90 minutes.  
 
Table 2.10. First strand synthesis reaction mix formula. 
Reagent Volume 
dNTP Mix (Thermo Fisher, R0192) 5mM 1 μL 
BioP5N7 10μM 0.5 μL 
NE Buffer (BioLabs, B7002S) 10X 0.5 μL 
Total 4 μL 
 
 Incubation was paused upon completion of the 90-minute incubation at 37°C, 
and 1 μL of Exonuclease I (NEB, M0293L) was added to the reaction mix to remove 
any unbound single strand DNA fragments. Incubation was then resumed at 37°C for 
an additional 60 minutes. 
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 Upon the completion of first strand synthesis, DNA fragments were purified 
through SPRI purification. During SPRI purification, 20 μL of solid phase reversible 
immobilisation (SPRI) beads were diluted in polyethylene glycol-electrolyte (PEG) 
solution, which could bind to DNA fragments larger than 200 bp in size. SPRI beads 
were then subsequently washed twice with 90% ethanol solution, removing fragments 
that are smaller than 200 bp (including unannealed primers). DNA fragments were 
then dissociated from SPRI beads through elution with 100 μL of TE buffer. 
Purified DNA fragments were captured with streptavidin coated Dynabeads® 
(Thermo Fisher Scientific, 11205D) in a process known as “Biotin Capture”. During 
biotin capture, Dynabeads were first prepared by removing the supernatants and 
suspending beads in Binding and Washing (B&W) Buffer (Table 2.11). 100 μL of 
resuspended Dynabeads were then added to the reaction mix and incubated on 
rotation for 20 minutes, allowing DNA fragments to be captured by Dynabeads. Once 
incubation was completed, Dynabeads were washed twice with 100 μL of freshly 
prepared 0.1M sodium hydroxide (NaOH) solution, followed by two additional washes 
with 100 μL of 10 mM Tris solution.  
 
Table 2.11. 2X binding and washing (B&W) buffer formula. 
Reagent Quantity 
Tris-HCl (pH7.5) 10 mM 
EDTA 1 mM 
Sodium chloride (NaCl) 2 M 
 
 Once washed, Dynabeads were resuspended in 48 μL of Second Strand 
Synthesis Reaction Mix (Table 2.12) for second strand synthesis. P7N7 primers were 
used as reverse primer during second strand synthesis, P7N7 primer contains a P7 
adaptor sequence and a random 7 bp oligonucleotide sequence. Reaction mixes were 
first incubated at 95°C for 45 seconds, then cooled to 4°C for 5 minutes while 2 μL of 
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Klenow Fragment (3’-5’ exo-) (NEB, M0212L) was added. Incubation temperature was 
then increased gradually from 4°C to 37°C at 6°C per minute, once temperature 
reached 37°C, the reaction mix was further incubated for 90 minutes. 
 
Table 2.12. Second strand synthesis reaction mix formula. 
Reagent Volume 
dNTP Mix (Thermo Fisher, R0192) 5mM 2 μL 
P7N7 10μM 2 μL 
NE Buffer (BioLabs, B7002S) 10X 5 μL 
Water 39 μL 
Total 48 μL 
 
 Upon completion of second strand synthesis, Dynabeads were first washed with 
50 μL of TE buffer, and resuspended in 11 μL of PCR Reaction Mix for DNA fragment 
amplification (Table 2.13). Forward and reverse primer used during PBAT PCR were 
obtained from Otago Index-F and Otago Index-R collections (gift from Les McNoe, 
Otago Genomics Facility). A unique combination of indices was assigned to each 
sample, allowing them to be identified individually following sequencing on an 
Illumina MiSeq. Amplification of the final library was achieved using thermal cycling 
parameters of 13 × (94°C, 80 secs; 65°C, 30 secs; 72°C, 30 secs) under “PBAT-PCR’. 
Table 2.13. PBAT PACR reaction mix formula. 
Reagent Volume 
KAPA HiFi HotStart Uracil+ ReadyMix (2X) (KK2802) 6 μL 
Water 5 μL 
Forward Primer 5μM 0.5 μL 
Reverse Primer 5μM 0.5 μL 
Total 11 μL 
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Once DNA fragments were amplified, quality of the amplified sample was 
examined through gel electrophoresis. Once library quality was confirmed, 3 μL of 
DNA was removed from each sample and pooled together, TE buffer was added until 
library was 100 μL in volume. Library was then purified by mixing the sample with 80 
μL of PEG-diluted SPRI beads. The SPRI beads were then washed twice with 100 μL of 
90% ethanol solution to removed unbounded primers. Supernatants were removed 
after second ethanol wash, and the beads was allowed to air-dry for 5 minutes. DNA 
fragments were then eluted with addition of 15 μL of water and collected for 








Figure 2.4. Post-bisulphite adaptor tagging (PBAT) experimental outline.  
Purified DNA was fragmented through bisulphite treatment. Adaptor tagged primers (Biotin-P5N7) 
were used to synthesise the first strand from the original genomic DNA, which were later captured 
using streptavidin coated Dynabeads. A second strand was synthesised from the first strand using 
P7N7 primer. First and second strands were then amplified by PCR, leading to the creation of a library, 
which was then purified and pooled together before they were sequenced for cytosine methylation. 
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3 CHAPTER 3   
RESULTS 
The underlying aim of this project was to explore novel ways to create and erase 
epigenetic memory in mammalian cells. To achieve this, forced expression of a plant 
methyltransferase (CMT3) and an amœboid demethylase (Naegleria TET), was 
undertaken in mouse embryonic stem cell lines. Flow cytometry was used to separate 
the CMT3/TET overexpression cells from non-expressing control counterparts, and 
low-coverage bisulphite sequencing was used to quantify their respective methylation 
levels. In doing so, I discovered that although forced expression of CMT3 did not 
increase CHG methylation as anticipated, and an unexpected increase in CG level was 
observed. I also discovered that whilst mammalian TET does have role in DNA 
methylation removal, the overexpression of Naegleria TET hydroxylase led to a 
paradoxical increase in DNA methylation level. 
 
3.1 Cell line establishment overview 
To establish cell lines with stable transgene expression, the genes-of-interest (CMT3/ 
TET variants) were shuttled into the pB-tetO2-mCherry expression vector prior to 
transfections. This vector contains a Tet-On activation system, allowing transgene 
expression to be induced in the presence of doxycycline (DOX) (Gossen et al., 1995). 
Through the use of an IRES sequence, pB-tetO2-mCherry co-expresses the monomeric 
cherry fluorescent protein (mCherry) gene alongside the gene-of-interest, thus acting 
as a reporter (Kaufman, Davies, Wasley, & Michnick, 1991).  During synthetic CHG 
methylation creation experiment, CMT3 methyltransferase was introduced to three 
mouse embryonic stem cell lines: two wild-type lines (E14 & V6.5) and a third DNMT 
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triple knockout (DNMT-TKO) line (Table 3.1). The use of wild-type lines allows the 
potential for CMT3 to establish CHG methylation in the presence of pre-existing 
mammalian to be tested, whereas the use of methylation deprived DNMT-TKO line 
could test the ability for CMT3 to establish methylation in the absence of CG 
methylation. During the DNA methylation removal experiment, TET variants were also 
transfected into three mouse embryonic stem cell lines: two wild-type lines (E14 & 
V6.5) and a third TNGA line (Table 3.1). While the use of wild-type lines allows effects 
of TET hydroxylase overexpression on global methylation to be observed, 
overexpressing mTET1-CD in TNGA cell line could test its suitability as a reporter 
system for site-specific DNA methylation alteration.  
 
Table 3.1. Transfected cell line establishment overview. 
Transgene 
Transfected cell line 
TNGA Wild-type (E14 & V6.5) DNMT-TKO 
mTET1-CD TNGA mTET1-CD Wild-type mTET1-CD  
WT nTET  Wild-type WT nTET  
nTET A212T  Wild-type nTET A212T  
nTET A212N  Wild-type nTET A212T  
nTET A212V  Wild-type nTET A212T  
CMT3  Wild-type CMT3 DNMT-TKO CMT3 
Control TNGA Control Wild-type control DNMT-TKO control 
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3.2 CMT3 transfected cell line establishment  
Due to its role in maintenance of CHG trinucleotide methylation in plant 
(Chodavarapu et al., 2010; Law & Jacobsen, 2010), I hypothesised that forced 
expression of the CMT3 methyltransferase in a mammalian cell may produce a novel 
form of epigenetic memory.  
3.2.1 CMT3 vector cloning 
The pDONR221-CMT3 vector (purchased from GenScript, OAa24945) (Figure 3.1a) 
was shuttled into the pB-tetO2-Cherry and pB-DEST-HYG expression vectors through 
LR recombination to form pB-tetO2-Cherry-CMT3 and pB-DEST-HGY-CMT3 vectors 
respectively (Figure 3.1b, d). Destination vectors were cloned through bacterial 
transformation. Five pB-tetO2-Cherry-CMT3 transfected bacterial colonies were 
cultured to amplify vectors within. Presence of CMT3 sequence in each clone was 
initially tested through MspI (HpaII) enzyme restriction digest (Figure 3.1c). The MspI 
enzyme was predicted to digest pB-tetO2-Cherry-CMT3 at 20 different sites, 
generating 20 fragments of various lengths, but most importantly, cleaving the CMT3 
coding sequence to generate three distinctive bands of 457, 721 and 791 bp (Figure 
3.1c). 
 Due to low LR recombination success rate of pB-DEST-HYG-CMT3 vectors, 16 
bacterial colonies transformed with pB-DEST-HYG-CMT3 LR recombination reaction 
mix were cloned to amplified vectors within (Figure 3.1e). Colony PCR was carried out 
for all colonies using CMT_F2 and CMT_R2 primers, however only colony V, VIII and 
XIII appeared to contain CMT3 sequence. Presence of CMT3 sequence in these clones 
were further confirmed through diagnostic PCR and DNA sequencing (Figure 3.1f & 
Figure 3.2). As shown in both analysis, it appears that CMT3 sequence can only be 
observed in colony V and XIII, and it is likely that CMT3 sequence amplified from 
colony VIII during colony PCR were false positives (Figure 3.1f). 
 




















Figure 3.1.  The cloning and Gateway shuttling of CMT3 sequence into entry and destination 
vectors.  
A) Graphical representation of pDONR211-CMT3 vector, B) Graphical representation of pB-tetO2-
Cherry-CMT3 vector, C) pB-tetO2-Cherry-CMT3 clone restriction digest with MspI enzyme, the 
horizontal dotted lines represent the location at which the cleaved CMT3 fragments were observed, D) 
Graphical representation of pB-HYG-CMT3 vector, E) pB-HYG-CMT3 vector colony PCR & F) pB-HYG-
CMT3 clone V, VIII, XIII diagnostic PCR. Bioline HyperLadder™ IV was used as a reference for band 
sizing (Supplementary figure 8a). 
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3.2.2 CMT3 vector sequencing 
Correct identity of the CMT3 coding sequence was confirmed by Sanger sequencing. 
CMT3 is a plant methyltransferase gene that contains 2,517 bp and 839 amino acids 
(XM_002888688), and as such is too long to be sequenced by a single pair of forward 
and reverse primers. As each extension during Sanger sequencing technique would 
typically produce around 1,000 bp of high quality sequence, two sets of primers 
(CMT_seqF1, R1 and CMT3_seqF2, R2) were used (Figure 3.2). No nucleotide 
variation was observed in our constructs between CMT3 sequence used and the 
reference sequence (XM_002888688) (Figure 3.3), indicating that no mutation has 
arisen during sub-cloning. 
 
 
Figure 3.2. CMT3 vector sequencing strategy.  
The forward primer was designed to be upstream of the reverse primer, allowing overlaps between the 
two primer sequences. First pair of primers (F1 & F2) were designed to be centred at the 586th base pair 
of the CMT3 sequence, allowing R1 sequence to extend beyond the 3’ end of the CMT3 gene. Whilst 
second pair of primers were designed to be centred at 1806th base pair of CMT3 gene, allowing F2 
sequence to extend beyond the 5’ end of the CMT3 gene. Primer pairs were also designed so that 
overlap was observed between the F1 and R2 primer extension sequence, ensuring complete 
sequencing of CMT3 gene. 




Figure 3.3. CMT3 sequencing result.  
CMT3_seqF1 primer extension sequence was compared to reference sequence, this figure contains 
sequence from the 1125th to 1190th nucleotide of CMT3 gene. 
 
  
CREATING A NEW CODE  CHAPTER 3 | RESULTS 
45 
 
3.2.3 CMT3 transfection FACS Analysis 
Once stable cell lines were established and transgene expression was initiated with 
DOX, CMT3 overexpressing E14 & V6.5 cells were sorted and collected in triplicate by 
FACS at the University of Otago flow cytometry facility. The number of cell collected 
from each cell sample during FACS is presented in the following table:  
 
Table 3.2. CMT3 transfected E14 & V6.5 cell culture analysis collection set up. 
Position Cell Culture Fluorescence Number collected 
A1 E14 Dox I Cherry 2,469 
B1 E14 Dox I Negative 1,596 
C1 V6.5 Dox I Cherry 665 
D1 V6.6 Dox I Negative 675 
E1 V6.5 Dox II Cherry 891 
F1 V6.5 Dox II Negative 961 
G1 V6.5 Dox III Cherry 6,319 
H1 V6.5 Dox III Negative 6,544 
A2 E14 Dox II Cherry 5,005 
B2 E14 Dox II Negative 757 
C2 E14 Dox III Cherry 5,000 
D2 E14 Dox III Negative 961 
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Cell samples were separated into mCherry expressing and non-mCherry 
expressing populations based on two selection gates. The threshold above which cells 
were considered as positive for mCherry was established using maximum fluorescence 
level of an E14 non-DOX treated during trial FACS, and as such was significantly 
higher than the negative gate, allowing two cell populations to be clearly differentiated 
(Figure 3.4). The same sets of positive and negative gates were used for both E14 and 
V6.5 cell lines. The complete set of CMT3 transfected E14 and V6.5 FACS scatter plots 
are presented in Supplementary figure 5. 
 
  
Figure 3.4. CMT3 overexpression FACS selection gate configuration.  
(Left) Non-DOX treated control and (right) DOX induced CMT3 transfected E14 I. The positive gate 
(P4) was set to be higher than maximum fluorescent level (PE TexRd-A) observed in the control cell line 
(left). Cells that have fluorescent level within the P4 range (purple dots) were collected and analysed as 
CMT3 overexpressed cell. The negative gate (P6) was set to have significantly lower fluorescent level 
than the positive gate, cells whose fluorescent level was within the P6 range (grey dots) were collected 
and analysed as non-expressing controls. 
 
The ratio of cell collected for mCherry+ and mCherry- from CMT3 transfected 
E14 and V6.5 cells are presented in the following table. As seen in Table 3.3 and Table 
3.4. E14 cell lines have a significantly higher mCherry expression level (5.4% average) 
in comparison with V6.5 cell lines (0.4% average) (p=0.000006). This suggests that 
the CMT3 gene was established with a much greater efficiency across E14 cell line then 
in V6.5 cell line. 
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Table 3.3. mCherry expression percentage of CMT3 transfected E14 cell lines. 
 mCherry+ mCherry- 
Control 0.1% 96.1% 
E14 CMT3 I 5.7% 84.3% 
E14 CMT3 II 5.4% 85.1% 
E14 CMT3 III 5.2% 84.7% 
 
Table 3.4. mCherry expression percentage of CMT3 transfected V6.5 cell lines. 
 mCherry+ mCherry- 
V6.5 CMT3 I 0.4% 94.2% 
V6.5 CMT3 II 0.3% 95.0% 
V6.5 CMT3 III 0.5% 94.5% 
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3.2.4 Wild-type CMT3 transfection bisulphite sequencing 
Following FACS analysis, total nucleic acid (TNA) was extracted from the cell samples 
and subjected to post-bisulphite adaptor tagging (PBAT). The resulting libraries 
consist of a faint smear from 100 to 1,000 bp, as expected for PBAT, albeit the quantity 
of DNA fragments amplified during PBAT PCR was low (Figure 3.5). The libraries 
created were sequenced, overexpression of CMT3 has led to a consistent increase in 
average CG methylation level across E14 (67.5% to 74.9%) and V6.5 (69.8% to 74.1%) 
cell lines, and the increase was statistically significant within the E14 line (p=0.043). 
(Figure 3.6a).  
 However, no significant changes were observed in average CHG methylation 
level across both E14 (1.0% to 1.3%) (p=0.203) and V6.5 (1.8% to 1.6%) (p=0.502) cell 
line (Figure 3.6b). A similar trend was also observed in average CHH methylation level, 
where there were no significant changes in CHH methylation level in association with 
CMT3 overexpression in both E14 (0.8% to 1.0%) (p=0.168) and V6.5 (1.4% to 1.3%) 
(p=0.383) cell lines (Figure 3.6c). Statistical significance of the result obtained were 
calculated through Student’s-T-test.  The read number and methylation percentage 
obtained from each cell sample during bisulphite sequencing is presented in 
Supplementary table 7. 
 
Figure 3.5. PBAT libraries of CMT3 transfected wild-type cell line samples.  
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                                                A) 
 
 
                                                B) 
 
 
                                                C) 
              
Figure 3.6. Average methylation level in E14 & V6.5 mouse embryonic stem cell populations with 
CMT3 overexpression versus no CMT3 expression (control).  
A) for CG methylation, B) CHG methylation and C) CHH methylation. n=3, ±S.D. 
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3.2.5 DNMT-TKO CMT3 transfection attempt  
It was hypothesised that the transfection of CMT3 into DNMT-TKO, a methylation-
deprived line, followed by temporary de novo methyltransferase expression, could test 
the ability for CMT3 to establish CHG methylation independently of CG methylation. 
Numerous attempts were made to introduce CMT3 gene into DNMT-TKO cell line 
during the present study. However, due to blasticidin, puromycin and hygromycin 
resistance exhibited by DNMT-TKO cell line (Okano et al., 1999), the presence of 
CMT3 was unable to be selected for with the expression vectors available. Therefore, 
CMT3 transfection into DNMT-TKO was carried out without antibiotics selection. In 
addition to the CMT3 transfected cell line, a pB-DEST-HYG-Cherry transfected 
positive control and untransfected negative control were also established. The 
experiment was conducted in triplicate; nucleic acids were extracted following the 
protocol given (§ Section 2.15) (Figure 3.7). Extracted DNA was subjected to diagnostic 
PCR to investigate transfection efficiency.  
 
 
Figure 3.7. DNMT-TKO CMT3 transfection TNA extract.  
The bright band at the top of the image is genomic DNA, whereas the three fainter bands at 2,000, 1,000 and 100 
bp length are 28s rRNA, 18s rRNA and 5s rRNA respectively. Bioline HyperLadder™ 1kb was used as a reference 
for band sizing (Supplementary figure 8b). 
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The diagnostic PCR revealed that, although CMT3 has been integrated into 
some cells from the transfected cultures (Figure 3.8), the transfection success rate was 
extremely low; a 1/50 times dilution of TNA extract was required for the presence of 
CMT3 sequence to be detected using diagnostic PCR. In contrast, 1/1000 dilution would 
usually suffice for detection of transfected sequences from colonies with moderate 
transfection success rate (data not shown).  
 
 
Figure 3.8. DNMT-TKO CMT3 transfection diagnostic PCR. 
The CMT3 sequence were observed across pB-DEST-HYG-CMT3 transfected cell cultures as a faint 
band at around 100 base pairs length. The PCR products ran on gel electrophoresis for this photo were 
diluted 50 times in Milli-Q water. Bioline HyperLadder™ IV was used as a reference for band sizing 
(Supplementary figure 8a). 
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3.2.6 DNMT-TKO Bisulphite Sequencing 
As the DNMT-TKO cell line overexpressing CMT3 was unlikely to have significant 
expression (Figure 3.8), it was decided not to push ahead with sequencing this line. 
Nevertheless, the untransfected DNMT-TKO cell line (which should be deprived of 
methylation), provides a useful control DNA from which the robustness of the PBAT 
methylation pipeline could be assessed. As such, untransfected DNMT-TKO total 
nucleic acid extract were subjected to PBAT treatment, the resulting libraries were then 
submitted for Illumina sequencing (Figure 3.9). As seen in Figure 3.9, DNMT-TKO 
PBAT libraries could be observed from across the 9th to 11th lane. A smear was observed 
across all samples, from 100 to 1,000 bp, as expected for PBAT libraries. The 
consistency in smear fluorescent intensity suggest that DNA fragments were amplified 
to a similar abundance across all samples. 
 
 
Figure 3.9. PBAT PCR amplified libraries of DNMT-TKO CMT3 transfected samples. 
Bioline HyperLadder™ IV was used as a reference for band sizing (Supplementary figure 8a). 
Global methylation levels of untransfected DNMT-TKO samples are presented 
in Figure 3.10. As seen in Figure 3.10, the DNMT-TKO cell samples are largely devoid 
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of DNA methylation, although residue CG, CHG and CHH methylation at 0.63%, 
0.53% and 0.47% could be observed respectively. Accuracy of the PBAT bisulphite 
sequencing technique were tested by comparing methylation levels obtained from the 
present study to previous experimental observations made on DNMT-TKO genomic 
methylation level (Tsumura et al., 2006). The comparison revealed that the global 
DNMT-TKO methylation level obtained during the present study are largely consistent 
with previous observation of around 0.4% for CG methylation and 0.1-0.4% for non-
CG methylation (Tsumura et al., 2006). The number of reads and methylation 
percentage obtained during bisulphite sequencing is presented in Supplementary table 
8. 
Statistical significance in the difference of data obtain between various 
experimental groups were calculated using Student’s T-test. 
 
Figure 3.10. Average genomic methylation level across CG, CHG & CHH context in DNMT-TKO 
cells. 
 n=3, ±S.D. 
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3.3 Naegleria TET transfected cell line establishment 
Differentiated cell types are characterised by high levels of epigenetic memory in the 
form of CG methylation. To assist in the removal of this epigenetic memory during 
formation of pluripotent stem cells, I overexpressed several TET variant proteins which 
precipitate DNA demethylation by oxidation. These TET variants consisted of murine 
TET1 catalytic domain (as a model mammalian TET protein) and four TET enzyme 
variants derived from the amœba Naegleria gruberi. The first of these Naegleria TET 
(nTET) sequences is essentially the unmodified protein sequence, as taken from the 
amœboid and has been shown in vitro to demethylate 5mC more rapidly than 
mammalian TET (Jurkowski T.P., unpublished). This superior oxidative capacity is 
likely due, at least in part, to the ability of nTET to efficiently oxidise 5hmC to 5fC and 
5caC compared to mammalian TET. This enhanced ability of nTET can be abolished by 
mutations of a key alanine residue in the catalytic site (three mutations have so far 
been made; A212T, A212N, A212V, Jurkowski T.P., unpublished).  
 
3.3.1 Naegleria TET vector cloning  
While cloned nTET variants were supplied to me by Tomasz Jurkowski, they were not 
immediately suitable for overexpression. To address this, I amplified the entire coding 
sequencing of the four nTET variants using common primers possessing both a nuclear 
localisation signal and ‘attachment’ sites for Gateway recombination (Table 2.3). 
Gradient PCR was carried out to find the optimal annealing temperature for these 
primers, which was apparently around 64-65°C (Figure 3.11a). Amplified DNA 
fragments were extracted from agarose gel and recombined into the entry vector, 
pDONR221, by the BP reaction (Figure 3.11b).  
Four transformed colonies for each nTET variant were screened for correct 
recombination. Initially, this was done by restriction digestion; if recombination was 
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successful, the Bsp1407I enzyme was predicted to produce three bands (191, 835 and 
2514 bp respectively, Figure 3.11c).  
nTET sequences were then shuttled from the expression vector into the pB-
tetO2-ires-Cherry destination vector (Supplementary figure 2) using LR 
recombination, thus creating pB-tetO2-Cherry-nTET vectors (Figure 3.11d). The 
presence of nTET in the destination vectors was confirmed through Bsp1407I enzyme 
restriction digest (four fragments predicted at 191, 835, 1341 and 4789 bp respectively, 
Figure 3.11e).  
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Figure 3.11. The cloning of nTET sequences and Gateway shuttling of nTET sequence into entry 
and destination vectors. 
 A) The PCR optimisation of wild-type and mutant (A212T, A212N & A212V) cloning from 64-66°C. B) 
Graphical representation of pDONR221-nTET vector. C) pDONR211-nTET vectors Bsp1407I restriction 
enzyme digest. D) Graphical representation of pB-tetO2-Cherry-nTET vectors. E) pB-tetO2-Cherry-
nTET vectors Bsp1407I restriction enzyme digest. Bioline HyperLadder™ 1kb was used as a reference 
for band sizing (Supplementary Figure 8b). 
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3.3.2 Naegleria TET Vector Sequencing 
In order to confirm that the sequence of the pB-tetO2-Cherry-nTET vectors was 
correct, I undertook conventional Sanger sequencing using primers nTET_F1 and 
nTET_R1 (Table 2.3), which centred on the 450th nucleotide of nTET sequence (Figure 
3.12). Naegleria TET sequence obtained from T.P. Jurkowski was used as a reference 
(Supplementary figure 4).  
 
Figure 3.12. nTET primer sequencing strategy.  
The F1 primer was designed to be upstream of the R1 primer, allowing “overlap” to occur at the centre 
of the nTET gene sequence, ensuring complete coverage of nTET gene sequence. The F1 and R1 
primers were also positioned so that the sequence extension of F1 primer was long enough to extend 
over the 3’ end of the nTET sequence and vice versa for the R1 primer sequence, allowing the complete 
coverage of nTET sequence. 
No variation in nucleotide sequences were observed between wild-type nTET 
sequence and the reference sequence supplied by Jurkowski. On the other hand, for 
each nTET variant (A212T, A212N, A212V), there were mutations in the coding 
sequencing at nucleotides 634-636, corresponding to the intended amino acid change 
(Figure 3.13A-B). In addition, there was a silent mutation (G to T) at the 627th bp for all 
three nTET mutant (A212T, A212N and A212V) sequences. It is highly unlikely that 
this mutation occurred independently in these three amplifications. As such, I 
conclude it must have been present in the original clone from which Jurkowski 
constructed the three variants.  
  







Figure 3.13. nTET Vector sequencing result.  
A) This figure contains sequence from the 590th nucleotide to the 680th nucleotide of Naegleria TET 
gene sequence. While wild-type nTET sequence is identical to the reference sequence, in A212T 
mutant the original G is replaced by an A on the 634th nucleotide, in A212N mutant, the original CGG 
was replaced by a ATT trinucleotide from the 634-636th nucleotide, in A212V the original CG was 
replaced by an TT dinucleotide from the 635-636th nucleotide. B) Translated amino acid sequence 
obtained from the four nTET variants indicating the presence of desired amino sequence alteration 
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3.3.3 TET overexpression 
The pB-tetO2-nTET and pB-tetO2-mTET1-CD constructs were transfected into E14 
and V6.5 mice embryonic stem cells. Following puromycin selection for the rtTA 
containing plasmid, three biological replicas were established for each transfected cell 
line, and DOX was added to induce transgene expression. Approximately 20,000 cells 
expressing the transgene (and non-expressing controls) were isolated by fluorescence 
activated cell sorting (FACS) on the basis of the linked mCherry reporter gene (Table 
3.5 & Table 3.6) 
 
Table 3.5. V6.5 TET variants transfection FACs cell count & collection tube co-ordination. 
Position Cell culture Cherry Expression Cell Count  
A1 V6.5 mTET1-CD I Cherry ~20,000 
B1 Negative 19,919 
C1 V6.5 mTET1-CD II Cherry 20,073 
D1 Negative 20,057 
E1 V6.5 mTET1-CD III Cherry  20,065 
F1 Negative 20,329 
G1 V6.5 nTET template I Cherry 20,078 
H1 Negative 20,654 
A2 V6.5 nTET template II Cherry 20,040 
B2 Negative ~20,000 
C2 V6.5 nTET template III Cherry  20,073 
D2 Negative 20,824 
E2 V6.5 nTET A212T I Cherry 20,038 
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Position Cell culture Cherry Expression Cell Count  
F2 Negative 21,403 
G2 V6.5 nTET A212T II Cherry 20,032 
H2 Negative 20,426 
A3 V6.5 nTET A212T III Cherry  20,039 
B3 Negative 20,377 
C3 V6.5 nTET A212N I Cherry 17,038 
D3 Negative 13,013 
E3 V6.5 nTET A212N II Cherry 6,292 
F3 Negative 2,212 
G3 V6.5 nTET A212N III Cherry  3,912 
H3 Negative 939 
A4 V6.5 nTET A212V I Cherry 20,029 
B4 Negative 20,737 
C4 V6.5 nTET A212V II Cherry 20,053 
D4 Negative 20,771 
E4 V6.5 nTET A212V III Cherry  20,034 
F4 Negative 20,375 
G4 pB-tetO2-ccdB-ires-Cherry I Cherry N/A 
H4 Negative 20,402 
A5 pB-tetO2-ccdB-ires-Cherry II Cherry N/A 
B5 Negative 21,304 
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Position Cell culture Cherry Expression Cell Count  
C5 pB-tetO2-ccdB-ires-Cherry III Cherry  N/A 
D5 Negative 20,902 
 
E5 Control I Negative 22,151 
F5 Control II Negative 21,863 
G5 Control III Negative 21,310 
 
Table 3.6. E14 TET variants transfection FACS cell count & collection tube co-ordination. 
Position Cell culture Cherry Expression Cell Count  
A1 E14 mTET1-CD I Cherry 20,075 
B1 Negative 20,583 
C1 E14 mTET1-CD II Cherry 20,105 
D1 Negative 21,173 
E1 E14 mTET1-CD III Cherry  20,063 
F1 Negative 20,770 
G1 E14 nTET template I Cherry 10,014 
H1 Negative 11,581 
A2 E14 nTET template II Cherry 10,013 
B2 Negative 23,985 
C2 E14 nTET template III Cherry  10,024 
D2 Negative 11,509 
E2 E14 nTET A212T I Cherry 10,013 
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Position Cell culture Cherry Expression Cell Count  
F2 Negative 10,882 
G2 E14 nTET A212T II Cherry 10,011 
H2 Negative 10,615 
A3 E14 nTET A212T III Cherry  10,016 
B3 Negative 10,878 
C3 E14 nTET A212N I Cherry 5,009 
D3 Negative 5,569 
E3 E14 nTET A212N II Cherry 5,006 
F3 Negative 6,200 
G3 E14 nTET A212N III Cherry  5,004 
H3 Negative 5,406 
A4 E14 nTET A212V I Cherry 5,006 
B4 Negative 5,375 
C4 E14 nTET A212V II Cherry 5,005 
D4 Negative 5,471 
E4 E14 nTET A212V III Cherry  5,007 
F4 Negative 5,821 
G4 E14 pB-tetO2-ccdB-ires-Cherry I Cherry N/A 
H4 Negative N/A 
A5 E14 pB-tetO2-ccdB-ires-Cherry II Cherry N/A 
B5 Negative N/A 
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Position Cell culture Cherry Expression Cell Count  
C5 E14 pB-tetO2-ccdB-ires-Cherry III Cherry  N/A 
D5 Negative N/A 
 
E5 Control I Negative 20,876 
F5 Control II Negative 20,854 
G5 Control III Negative 22,311 
 
Cell samples were separated into mCherry expressing population and non-
mCherry expressing population based on two selection gates. The threshold above 
which cells were considered as positive for mCherry was established using maximum 
fluorescence level of V6.5 Control I colony during trial FACS and as such was 
significantly higher than the negative gate, allowing two cell populations to be clearly 
differentiated (Figure 3.14). The same sets of positive and negative gates were used for 
both E14 and V6.5 cell lines.  
  
Figure 3.14. TET variant overexpression FACS selection gate configuration.  
(Left) Non-DOX treated control and (right) DOX induced mTET1-CD transfected V6.5 cultures. The 
positive gate (P4) was set to be higher than maximum fluorescent level (PE TexRd-A) observed in the 
control cell line (left). Cells that have fluorescent level within the P4 range (purple dots) were collected 
and analysed as TET overexpressed cell. The negative gate (P6) was set to have significantly lower 
fluorescent level than the positive gate, cells whose fluorescent level was within the P6 range (grey 
dots) were collected and analysed as non-expressing controls. 




Ratio of cell sample collected as mCherry+ and mCherry- from each of the TET 
variants transfected cell lines during FACS are presented in Table 3.7 and Table 3.8. It 
was observed that except for mTET1-CD transfected groups, mCherry expression rates 
were significantly lower in E14 cell lines from every experimental group in comparison 
to V6.5 cell line (p=0.00110). This suggests that transfection success rate is lower in 
most E14 cell cultures then V6.5 cultures. It has also been noted that no mCherry+ 
cells were observed from pB-tetO2-ccdB-ires-Cherry transfected groups from both E14 
and V6.5, indicating that mCherry protein in the pB-tetO2-ccdB-ires-Cherry vector is 
likely to be defective. 
 
Table 3.7. Average mCherry expression percentage of TET variants transfected V6.5 cells line. 
Experiment groups mCherry+ mCherry- 
V6.5 mTET1-CD 5.3% 72.6% 
V6.5 WT nTET 5.7% 71.5% 
V6.5 nTET A212T 4.2% 75.7% 
V6.5 nTET A212N 3.1% 76.8% 
V6.5 nTET A212V 3.8% 74.1% 
V6.5 pB-tetO2-ccdB-ires-Cherry 0% 84.3% 
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Table 3.8. Average mCherry expression percentage of TET variants transfected E14 cells line. 
Experiment groups mCherry+ mCherry- 
E14 mTET1-CD 5.4% 78.1% 
E14 WT nTET 1.0% 90.1% 
E14 nTET A212T 1.2% 89.7% 
E14 nTET A212N 0.6% 91.2% 
E14 nTET A212V 0.3% 91.8% 
E14 pB-tetO2-ccdB-ires-Cherry 0% 93.3% 
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3.3.4 Bisulphite sequencing of cells overexpressing TET 
Once E14 and V6.5 TET variant transfected cell samples were sorted and collected, 
TNA was extracted (Figure 3.15) and subjected to post-bisulphite adaptor tagging 
(PBAT). The resulting libraries consisted of a DNA smear from 100 to 1000 bp, as is 
expected for PBAT (Figure 3.16 & Figure 3.17). The same co-ordinates were used for 
PBAT treated samples as those assigned during wild-type TET variants transfection 
FACS (Table 3.5 & Table 3.6).   
 
 
Figure 3.15. E14 & V6.5 TNA extract.  
Extraction efficiency were tested by running first 8 samples (A1-H1) from both cell lines on gel 
electrophoresis, the brighter band observed towards the top of the image are genomic DNA extracted, 
while the fainter bands at 2,000 and 1,000 base pair length are 28s rRNA and 18s rRNA respectively. 
Bioline HyperLadder™ 1kb was used as a reference for band sizing (Supplementary figure 8b). 
 
 




Figure 3.16. PBAT PCR amplified library of the V6.5 TET variants transfected samples.  
Bioline HyperLadder™ IV was used as a reference for band sizing (Supplementary figure 8a). 
 
  
Figure 3.17. PBAT PCR amplified library of the E14 TET variants transfected samples.  
Bioline HyperLadder™ IV was used as a reference for band sizing (Supplementary figure 8a). 
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To differentiate individual samples during bisulphite sequencing, DNA 
fragments from each sample were amplified with a unique combination of forward and 
reverse primers from Otago Index-F and Otago Index-R collections (Supplementary 
table 5 & Supplementary table 6).  
Following sequencing and bioinformatic analysis, CG methylation levels were 
recorded for each sample (Figure 3.18 & Figure 3.19). The average methylation level in 
non-DOX treated E14 control was 58.4% (Figure 3.18 & Figure 3.19), whilst the 
average methylation level for non-DOX treated V6.5 control was 70.0%. The difference 
in methylation levels observed between E14 and V6.5 cell lines are likely to a reflection 
of the different embryonic developmental stages at which these cell lines are obtained 
from (Rideout et al., 2000; A. G. Smith & Hooper, 1987). Overexpression of mTET1-CD 
led to a consistent and significant decrease in average genomic methylation level across 
both E14 (61.8% to 50.6%) (p=0.0043) and V6.5 (60.1% to 55.8%) (p=0.0455) cell 
lines.  
Overexpression of wild-type nTET was associated with a consistent increase in 
average methylation level across both E14 (57.8% to 62.9%) and V6.5 (66.6% to 70.4%) 
cell lines, although this was not statistically significant in either case (p=0.1086 and 
0.4655 respectively). No significant changes were observed in average methylation 
level following A212T nTET overexpression across both cell lines (E14: 56.8% to 55.2% 
and V6.5: 69.5% to 74.1%). A212N nTET is associated with no significant change in 
average methylation level in E14 (53.0% to 52.8%) cell line and a significant increase in 
V6.5 (67.2% to 77.2%) (p=0.0175) cell line. Overexpression of A212V nTET appeared to 
trigger a significant increase in average methylation in E14 (58.9% to 61.2%) 
(p=0.0101) and highly significant increase in V6.5 (65.8% to 76.7%) (p=0.0003) cell 
line. Number of reads and methylation obtained from TET variant overexpressed V6.5 
and E14 cell cultures during bisulphite sequencing are presented in Supplementary 
table 9 and Supplementary table 10 respectively. Statistical significance of the data 
obtained were calculated though Student’s T-test. 










Figure 3.19. V6.5 TET variant transfected cell line average methylation level.  
n=3, ±S.D. 
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3.3.5 TNGA mTET1-CD TET vector transfection FAC Analysis 
 
Whereas TET variant overexpression in wild-type embryonic stem cells allows their 
effect on global methylation level to be observed, mTET1-CD was transfected into the 
TNGA cell line to examine its potential as a reporter system for site-specific removal of 
DNA methylation. It was hypothesised that mTET1-CD overexpression is likely to 
trigger the demethylation at Nanog promoter sequence, resulting in the removal of 
Nanog gene suppression, which could be observed as an increase in GFP fluorescence 
(linked with Nanog expression) in transfected TNGA cells. The mTET1-CD transfect 
cell samples were analysed by flow cytometry at the Otago Facility. Transfected cell 
cultures were treated with 0.1% DOX for a 48-hour period prior to flow cytometry. The 
experiment was conducted in triplicates, and three cell cultures were left untreated 
with DOX to be used as a non-DOX negative control. During FAC analysis, 10,000 
events were collected from each sample, and divided into four groups based on their 
mCherry and GFP expression status: mCherry+/ GFP- (Q1), mCherry+/ GFP+ (Q2), 
mCherry-/ GFP- (Q3) and mCherry-/ GFP+ (Q4) cells (Figure 3.20). 
To analyse the effect of mTET1-CD demethylation on Nanog expression, cell 
samples were divided into two groups, mCherry+ (Q1 & Q2), where expression of 
transfected mTET1-CD were induced through DOX treatment, and mCherry- (control) 
(Q3 & Q4), with no mTET1-CD expression (Figure 3.20). To examine the robustness of 
TNGA cell line as a reporter system for site-specific demethylation, the association 
between mTET1-CD overexpression and Nanog gene expression was investigated. This 
was achieved by calculating the proportion of GFP+ cells (i.e. those with Nanog 
expression, reporting Nanog promoter demethylation) in two populations of cells; 
those mCherry+ (i.e. with mTET1-CD overexpression) and those mCherry- (without 
mTET1-CD expression).  
 
 





Figure 3.20. TNGA mTET1-CD transfection FAC analysis result.  
(Left) Non-DOX treated Control (nTET template), (right) mTET1-CD 
As seen in Figure 3.21, whilst no significant trends were observed in the Non-
DOX treated controls (39.3% of CFP+ cells in mCherry+ group versus 40.4% of GFP+ 
cells in mCherry– group), a significantly higher proportion of cells were expressing 
Nanog across mTET1-CD overexpressed groups (64.0%) (p=0.0161) in comparison to 
their non-mTET1-CD (44.1%) counterparts, and the difference in Nanog expression 
between the two groups was large (19.2%) (Table 3.9). Statistical significance of data 
obtained where calculated through Student’s t-test.  
 
Figure 3.21. Average GFP (Nanog) expression ratio of mTET1-CD overexpressed versus non-
overexpressed TNGA cell lines.  
n=3, ±S.D. 





Table 3.9. Average GFP expression percentage of mTET1-CD transfected TNGA cell across the 
mCherry+ and mCherry- groups. 
 mCherry+ mCherry- 
Negative control 39.3% 40.4% 
mTET1-CD 64.0% 44.1% 
 
The average mTET1-CD overexpression rate (percentage of cells collected as 
mCherry+) in transfected TNGA cell line is presented in the following table. As seen in 
Table 3.10, the rate of mTET1-CD overexpression is relative low, where only 
approximately 1% of cell collected are overexpressing mTET1-CD (mCherry+). 
Conversely, mCherry has been observed in 0.6% of the cells in the control group, 
suggesting that mTET1-CD might have been inappropriately activated in certain cases. 
 
Table 3.10. Average mCherry expression percentage of mTET1-CD transfected TNGA cells line. 
Experiment groups mCherry+ mCherry- 
mTET1-CD 1.0% 99.0% 
Control 0.6% 99.4% 
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4 CHAPTER 4 
DISCUSSION 
In this study, the potential of synthetic epigenetics was tested through two lines of 
research, where novel epigenetic modifiers (plant CMT3 methyltransferase and 
amœboid Naegleria TET hydroxylase) were integrated into the genome of mouse 
embryonic stem cells to induce epigenetic changes that are not usually associated with 
mammalian genomes. I attempted to introduce CHG methylation into wild-type mouse 
embryonic stem cells (E14 & V6.5) through transfection of plant-based CMT3 
methyltransferase. The present study shows no significant CHG methylation level 
increase in transfected mouse embryonic stem cells following CMT3 overexpression, 
however CMT3 overexpression appears to be correlated with a consistent increase in 
CG methylation increase across both cell lines.  
From in vitro studies, it has been shown that nTET proteins have increased 
demethylation efficiency compared to mammalian counterparts (Jurkowski T.P., 
unpublished), therefore wild-type nTET and, mutant nTET (A212T, A212N and A212V) 
were introduced into wild-type mouse embryonic stem cell (E14 & V6.5) to observe 
their effect on CG methylation. While overexpression of mTET1-CD was consistent 
with a global decrease in CG methylation, overexpression of nTET either had no effect 
on CG methylation, or significantly increased CG methylation levels. The 
overexpression of mTET1-CD in TNGA cell line was consistently associated with an 
increase in Nanog expression levels. 
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4.1 Analysis of CMT3 overexpression in wild-type mouse 
embryonic stem cells 
The objective of this experiment was to create a novel form of epigenetic memory (i.e. 
CHG methylation) in a mammalian cell. In order to do so, I overexpressed the CMT3 
methyltransferase in mouse embryonic stem cells, predicting that it would recognise 
hemi-methylated CHG nucleotides (Lister et al., 2009), and thus increase the level of 
CHG methylation in the genome. However, overexpression of CMT3 did not have a 
statistically significant effect on CHG methylation level (Figure 3.6b) 
I propose that the inability to increase CHG methylation is due to one of two 
reasons; firstly, CMT3 is unable to methylate mammalian DNA due to sequence 
incompatibility, or secondly, in a mammalian environment, CMT3 is lacking vital co-
factors required for its function. The hypothesis that sequence specificity is required 
for CMT3 function is based upon the observation that CHG methylation occurs 
predominantly within transposon and repetitive elements across Arabidopsis genome 
(Bernatavichute, Zhang, Cokus, Pellegrini, & Jacobsen, 2008; Feng et al., 2010; Zhang 
et al., 2006). CHG methylation distribution in plants might have been a result of CMT3 
methyltransferase sequence specificity. Under these circumstances, CHG methylation 
would have failed to become established in mammalian genome due to the lack of 










Figure 4.1. Sequence specificity in CHG methylation deposition.  
Under this hypothesis, the inability to establish CHG methylation is due to the sequence specificity of 
CMT3 methyltransferase, restricting it to deposit CHG methylation in plant-specific transposons. The 
lack of these sequences in mammalian genome meant that CMT3 cannot carry out its catalytic activity 
to establish CHG methylation in mouse embryonic stem cells.  
 A potential experimental model to test this hypothesis would involve creating a 
transgenic embryonic stem cell line containing a natural target of CMT3 (such as a 
plant repetitive sequence) and to see if CMT3 can create CHG methylation at this site.  
 Alternatively, inability to establish CHG methylation during the present study 
could also be explained by a lack of essential co-factors required for CHG methylation 
establishment. It has been postulated that CHG methylation in plants is dependent 
upon the existence of a positive feedback loop involving CMT3 histone 
methyltransferase known as KRYPTONITE (KYP) (Bernatavichute et al., 2008; T. Ito 
et al., 2015) (Figure 4.2). Currently, it is unclear if CMT3 is dependent upon KYP per 
se, or simply the H3K9me2 mark that it deposits. Given that mammalian embryonic 
stem cells possess high levels of H3K9me2 due to the action of G9a (Lindroth et al., 
2004; Shinkai & Tachibana, 2011), our experiment may suggest that CMT3 is 
dependent upon KYP itself.    
 
 




Figure 4.2. CHG methylation maintenance in plant.  
Although it has been previously suggested that CHG methylation maintenance in plant is controlled by 
a positive feedback loop, where CHG methylation deposited by CMT3 will lead to the localisation of 
KRP which deposits H3K9me2 histone tail modification for further CMT3 recruitment. The current 
experimental observation suggested that KYP might play a role in the direct recruitment of CMT3 to 
establish CHG methylation. 
 This hypothesis could be examined through potential experiments involving co-
transfection of CMT3 with KYP into wild-type and G9a knockout line (Sampath et al., 
2007), where endogenous H3k9me2 methylation has been removed. With these two 
experimental groups, it would be possible to investigate potential roles KYP could have 
in CMT3 methylation establishment and whether plant KYP, and whether mammalian 
G9a are functionally redundant in H3K9me2 histone methylation deposition. If this 
hypothesis is proven to be true, it would suggest that plant and mammalian epigenome 
are rather divergent in nature, and that the integration of entire epigenetic 
modification machinery are required for novel epigenetic markers to be created. 
A consistent moderate increase in CG methylation level was observed across 
both wild-type cell lines transfected with CMT3. This observation not only indicates 
that a functional protein was produced, but also suggests that CMT3 
methyltransferases could be more dynamic them previously assumed, and possess 
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some de novo or maintenance methylation capacity at CG dinucleotides. This 
possibility has been previously been suggested (Martienssen & Colot, 2001), although 
no experiment has hitherto been carried out to investigate this proposition. This result 
emphasises the value of overexpressing epigenetic modifiers in divergent systems as a 
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4.2 Analysis of CMT3 DNMT-TKO transfection experiment 
The objective of this experiment was to investigate whether CHG methylation could be 
established independently in the absence of pre-existing mammalian DNA methylation 
through transfection of CMT3 into DNMT-TKO cell line, which is devoid of DNA 
methylation. The intention was then to introduce transient de novo methylation into 
this transgenic cell line (using DNMT3A/3B expression from non-integrating 
plasmids), and thereby conduct a ‘pulse-chase’ experiment, with the hope of capturing 
definitive epigenetic memory in the CHG context (Figure 4.3). However, due to 
resistance to blasticidin, hygromycin and puromycin exhibited by DNMT-TKO (Okano 
et al., 1999; Tsumura et al., 2006), I was unable to select for the CMT3 transgene using 




Figure 4.3. Graphical representation of CHG methylation capture experiment.  
The ability for CMT3 to establish CHG methylation in the absence of pre-existing CG methylation in 
mammalian genome could be examined by introducing CMT3 into DNMT-TKO cell line. Which is 
followed by temporary de novo methylation through transfection of DNMT3A/3B pcDNA3 vectors, if 
CMT3 does indeed have CHG methylation maintenance activity it will result in the ‘capture’ of CHG 
methylation after the transient de novo methylation has worn off (i.e. differences in CHG methylation 
level observed between CMT3+ and untransfected DNMT-TKO cells). 




Nevertheless, bisulphite sequencing of untransfected DNMT-TKO was 
undertaken and did provide a useful control for my other experiments; average 
methylation levels were 0.56%, 0.53% 0.47% in the CG, CHG and CHH contexts 
respectively (Figure 3.10). These observations are consistent with previous attempts to 
measure methylation in DNMT-TKO cell lines (Tsumura et al., 2006), implying that 
my bisulphite analysis methods are robust. The efficiency of the bisulphite molecule to 
convert unmethylated cytosine to uracil is affected by the thermal cycling conditions 
used for treatment, and can vary depending upon the kit used and the cell type of 
origin (Leontiou et al., 2015). Using DNMT-TKO DNA as a control, I can confidently 
report that the protocol I used has a conversion efficiency in excess of 99.4%. 
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4.3 Analysis of TET variant overexpression in wild-type cell 
lines 
The objective of these experiments is to investigate whether it is possible to achieve 
more efficient demethylation in mouse embryonic stem cells through nTET 
transfection. The value in doing such an experiment is two-fold, not only could it 
provide greater insight into how divergent TET enzymes function in vivo, but also 
could provide a new tool to assist the removal of epigenetic memory, something which 
is essential for the creation of naïve induced pluripotent stem cells. To investigate 
nTET catalytic activity in vivo, three experimental groups were established during the 
present study: wild-type nTET transfected group, mutant nTET (A212T, A212N and 
A212V) transfected group and mTET1-CD transfected group. This experiment has 
generated two significant findings; a consistent decrease in global methylation 
following mTET1-CD expression, and an unexpected potential increase in global 
methylation following nTET overexpression.  
A consistent and significant decrease in CG methylation level was observed for both 
cell lines tested (E14 and V6.5) following mTET1-CD overexpression. This observation 
is consistent with previous findings where overexpression of TET1 catalytic domain in 
HEK293 cells causes global demethylation (Jin et al., 2014). Not only does this result 
support the general robustness of the overexpression system and bisulphite sequencing 
pipeline used, it also represents the first time global demethylation has been observed 
following TET1-CD overexpression in embryonic stem cells.  
In comparison to mTET1-CD, overexpression of nTET either had no effect on global 
methylation, or significantly increased it. This finding does not support my initial 
hypothesis and contrasts the observation that in vitro nTET oxidises 5mC with greater 
efficiently and oxidative extent, compared to mammalian TET (Jurkowski T.P., 
unpublished).  
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The disparity between in vitro and in vivo observation could potentially be 
attributed to the fact that although nTET and mammalian TET are conserve in their 
dependency on Fe2+ and α-ketoglutarate, they possess very divergent protein sequence 
(homology cannot be detected through standard protein BLAST search) (Iyer et al., 
2009; Tahiliani et al., 2009). Thus, nTET protein might not interact with essential co-
factor proteins due to sequence dissimilarity, but still sequester Fe2+ and α-
ketoglutarate in the cell, leaving less available for endogenous TET proteins (Figure 
4.4).  
 
Figure 4.4. Competition between mammalian and Naegleria TET for co-activator binding.  
Under this hypothesis, the overexpressed Naegleria TET compete with murine TET proteins for the 
binding of co-activators such as Fe2+ and α-ketoglutarate, reducing the catalytic activity of functional 
mammalian TET protein, leading to an overall increase in global methylation level. 
This hypothesis could potentially be tested through the creation of a mTET1 
catalytic mutant (mTET1-CD CatMut) with conserved Fe2+ and α-ketoglutarate binding 
site but a mutated CXXC domain. This catalytic mutant will also compete for Fe2+ ion 
and α-ketoglutarate uptake but not oxidise 5mC due to mutated catalytic domain. 
Alternatively, overexpression of various TET variants in TET triple knockout (TET-
TKO) (Dawlaty et al., 2014)  cell lines may also help separate the direct effect of nTET 
overexpression in the absence of interaction with endogenous TET.  
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4.4 Analysis of mTET1-CD overexpression in TNGA cell line  
The objective of this experiment is to establish a reporter system for site-specific 
alteration of DNA methylation, which could then be further utilised for future 
experimentations to test the efficiency of site-specific epigenetic modifiers. The TNGA 
cell line has been proposed as a potential candidate for a site-specific reporter system 
during the present study, as it has been noted that TNGA contains a GFP fluorescence 
gene which reports for the expression of Nanog (Chambers et al., 2007), which could 
be influenced by the methylation status at its promoter (Figure 4.5). The suitability of 
TNGA cell line as a site-specific methylation reporter system was examined through 
mTET1-CD overexpression during the present study. It was proposed that the 
overexpression of mTET1-CD transgene would lead to genome-wide methylation 
removal, which is likely to cause the demethylation at the Nanog promoter and 
observed as GFP fluorescence. 
  
Figure 4.5. TNGA Nanog expression reporter system. 
The TNGA cell line contains a GFP reporter gene that is linked to Nanog expression. The present study 
has readopted Nanog-GFP reporter as a site-specific methylation reporter system to detect the 
methylation status of the Nanog promoter. It was hypothesised that mTET1-CD overexpression could 
lead to global demethylation which might result in removal of methylation at Nanog promoter, this 
may be observed as GFP fluorescence as Nanog expression become derepressed. 
 
 A large and significant increase in the proportion of cells with Nanog (GFP 
fluorescence) expression was observed following mTET1-CD overexpression. This 
observation is consistent with the experimental hypothesis, suggesting that global 
methylation removal did lead to demethylation of the Nanog promoter sequence, 
inducing Nanog expression. Thus, TNGA cell line is considered as a suitable model for 
the reporting of site-specific methylation status.  
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 However, this experiment also revealed that Nanog is expressed in 40.4% of 
the cells in the absence of mTET1-CD overexpression. This is caused by the fact that 
Nanog is a pluripotency factor that is naturally expressed in embryonic stem cells 
(Chambers et al., 2003). As embryonic stem cell cultures are heterogenous in nature 
(Hayashi, Lopes, Tang, & Surani, 2008; Kalmar et al., 2009), it is likely that Nanog 
expression level would fluctuate in response to internal or culturing conditions 
(Abranches et al., 2014), potentially obscuring the experimental result obtained. 
Therefore, the site-specific reporter system could potentially be improved by using cell 
lines that report the expression of a loci that is normally suppressed through 
imprinting, such as mouse embryonic stem cells with a GFP reporter for the paternal 
derived Tel7KI (M. Jones & Lefebvre, 2009). Using these cell lines, it would be possible 
to attribute any fluorescence observed directly to the depression of the promoter 
sequence, due to changes in methylation status, enhancing the accuracy of the site-
specific methylation reporting system. 
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4.5 Targeted epigenomic editing 
In this research project, I have explored two potential ways to globally modify DNA 
methylation. However, site-specific epigenetic modifications are perhaps more likely to 
have biomedical applications; as induction of cellular reprogramming or cancer 
treatments are more likely to require targeted modulation of gene transcription, rather 
than genome-wide alteration of gene expression. Therefore, I propose that further 
research effort should be focused on the fusion and optimisation of novel epigenetic 
modifiers with gene targeting technologies to enhance their potential applicability in 
medical treatments. A loci-specific methylation reporter system (TNGA cell line) was 
examined during the present study, in hope that it could provide a useful tool to test 
the efficiency of site-specific epigenetic modification system for future 
experimentation. 
 Currently, three DNA binding domain (DBD) systems have been adapted for 
targeted modification of epigenome, these include; zinc finger proteins (ZFPs), 
transcription activator-like effector nuclease (TALEs) and the CRISPR/dCas9 system 
(Boch et al., 2009; Gersbach, Gaj, & Barbas III, 2014). CRISPR/dCas9 system appears 
to be the most promising technique due to its reliance on guide RNA (gRNA) rather 
than amino acid sequence for gene targeting (Qi et al., 2013). The use of gRNA 
complementarity as DNA targeting mechanism allows CRISPR/dCas9 to be redesigned  
effectively for targeting various loci (reviewed, Gupta & Musunuru, 2014).  
Therefore, it has been proposed and demonstrated that combining epigenetic 
modifiers (such DNMT3A and TET variants) with CRISPR/dCas9 could provide 
powerful tool to conduct site-specific modification of epigenomes (Choudhury, Cui, 
Lubecka, Stefanska, & Irudayaraj, 2016; Vojta et al., 2016; X. Xu et al., 2016). 
Additionally, the CRISPR/dCas9-epigenetic modifier system could be further improved 
through simultaneous targeting of multiple locus using multiple gRNAs (Cong et al., 
2013; Mali et al., 2013). This could significantly enhance the efficiency to reprogramme 
CREATING A NEW CODE  CHAPTER 4 | DISCUSSION 
85 
 
cell fate artificially through simultaneous regulation of multiple cell fate determining 
genes. 
 Alternatively, the development of a reliable in vivo administration method 
could also expand the therapeutic uses of targeted epigenetic modification technology, 
allowing in vivo reprogramming of cellular identity, as highlighted by the recent 
successful attempt at in vivo DNA methylation removal (Liu et al., 2016). Furthermore, 
advancements such as the discovery of a smaller Cas9 orthologue (Ran et al., 2015), 
has also allowed CRISPR-dCas9/epigenetic modifier fusion proteins to be delivered 
with greater efficiency using adeno-assisted virus (AAV), outlining their potentials in 
clinical applications (Thakore, Black, Hilton, & Gersbach, 2016). Taken together, the 
integration of epigenetic modifiers with the latest advancements in molecular biology 
could present the ultimate goal of synthetic epigenetics, whereby DNA methylation 
could be modified across several loci simultaneously, and be applied in vivo as well as 
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4.6 Concluding remarks 
This study represents part of a research effort to improve DNA methylation 
modification technology through investigating the catalytic activity of plant CMT3 and 
Naegleria TET within mouse embryonic stem cells. The synthetic CHG methylation 
experiment revealed that CMT3 methyltransferase appears to be unable to maintain 
CHG methylation in the absence KYP histone methyltransferase in mouse embryonic 
stem cells. Suggesting that creating novel epigenetic markers in mammalian genome 
may require the transfer of a complete epigenetic machinery, rather than a single 
epigenetic modifier. The artificial DNA methylation removal experiment revealed that 
contrary to in vitro observation, introduction of Naegleria TET into mouse embryonic 
stem cell will lead to an overall decline in demethylation efficiency. It has been 
hypothesised that this decrease in demethylation efficiency is caused by the sequence 
divergence between mammalian and Naegleria TET protein, and are unable to oxidise 
5mC in vivo. These observations suggest that modification of mammalian TET active 
site might represent a more efficient method to enhance DNA methylation removal. 
Although this research suggests that the modification of DNA methylation is more 
complicated than previously assumed, methods used during the present study have 
been demonstrated to be effective for DNA methylation editing and could be adapted 
for future studies. 
 






Supplementary figure 1. Graphical representation of pDONR211 vector.  
pBR322\origin, origin of transcription; attL1 & attL2, recombination attachment sites; ccdB, control of 
cell death B gene, providing a negative selection mechanism against non-recombined vector in 
bacterial culture & KanR, Kanamycin resistant gene, providing positive selection mechanism for the 
presence of the vector in the bacteria. 
 
 




Supplementary figure 2. Graphical representation of pB-tetO2-iresCherry Vector.  
PB\3’LTR/ PB\5’LTR, Long terminal repeat sequences,; tetO2, tetracycline operator 2 sequence, a 
sequences that is able to induce DNA transcription in the presence of tetracycline and its derivatives; 
mCMV\Promoter, (Murine cytomegalovirus promoter) a sequence that is able to promote the 
expression of the gene-of-interest; AttR1/ AttR2 site, recombination attachment sites; ccdB, control 
of cell death B gene, providing a negative selection mechanism against non-recombined vector in 
bacterial culture; IRES, (Internal ribosome entry site) a sequence that allows the expression of two 
genes within a single vector; mCherry, a red fluorescent protein, act as an reporter gene for gene-of-
interest; Rabbit\β-globin\pA, the poly-A-tail sequence; ColE1\origin, origin of transcription & AmpR, 
ampicillin resistance gene, providing a positive selection mechanism for the presence of vector in the 
bacterial culture.  
  




Supplementary figure 3.Graphical representation of the predicted sequence for pB-DEST-HYG 
vector.  
CMV IE, (cytomegalovirus-immediate early promoter) enhances the expression of gene-of-interest in 
mammalian cells; Actin Promoter, a promoter involved in inducing the expression of gene-of-interest 
in vitro; Chimeric Intron, an artificial intron used to stimulate the gene-of-interest expression in 
mammalian cell; ccdB, control of cell death B gene, providing a negative selection mechanism against 
non-recombined vector in bacterial culture; Hph, hygromycin B phosphotransferase, a hygromycin 
resistance gene that provides a positive selection mechanism for the presence of the vector in 
mammalian cells; PB\3’LTR & PB\5’LTR, Long terminal repeat sequences & AmpR, Ampicillin 
resistance gene, providing a positive selection mechanism for the presence of vector in bacteria during 
cloning. 
  




Supplementary figure 4. Naegleria TET1 hydroxylase nucleotide sequence 
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Supplementary figure 5. E14 & V6.4 CMT3 transfection scatter graph.  
A) E14 uninduced control, B) E14 CMT3 I culture, C) V6.5 CMT3 I culture*, D) E14 CMT3 II culture, E) 
V6.5 CMT3 II culture, F) E14 CMT3 III culture & G) V6.5 CMT3 III culture.    
                                                        
* V6.5 CMT3 I culture was mislabelled as “V6.5 No-DOX” During FACS 
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Supplementary figure 6. V6.5 TET variant transfection scatter graph.  
A) V6.5 uninduced control, B) V6.5 mTET1-CD transfected culture, C) V6.5 wild-type nTET transfected 
cell culture, D) V6.5 nTET A212T transfected cell culture, E) V6.5 nTET A212N transfected cell culture, 
F) V6.5 nTET A212V transfected cell culture & G) V6.5 pB-tetO2-ccdB-ires-Cherry transfected cell 
culture.    
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Supplementary figure 7. E14 TET variant transfection scatter graph.  
A) E14 uninduced control, B) E14 mTET1-CD transfected culture, C) E14 wild-type nTET transfected cell 
culture, D) E14 nTET A212T transfected cell culture, E) E14 nTET A212N transfected cell culture, F) E14   











Supplementary figure 8. Bioline HyperLadder™ molecular weight maker sizes.  









Supplementary table 1. Luria broth/ agar formula 
Luria Broth/ Agar Formula 
Material Per Litre 
Peptone from casein (Tryptone) 
Merck KGaA (1.07213.1000) 
10g 
Granulated yeast extract 
Merck KGaA (1.03753.0500) 
5g 
Sodium chloride (NaCl) pure Ph. Eur., USP 




Duchefa Biochemie (M1002.1000) 
15g 
 
Water (H2O) Add until solution is 1 litre in 
volume 
 
Supplementary table 2. Antibiotic usage & concentration 





Ampicillin Bacterial 100mg/mL 100μg/mL 
Kanamycin Bacterial 50mg/mL 50μg/mL 
Blasticidin Mouse embryonic stem cell 20mg/mL 20μg/mL 
Puromycin Mouse embryonic stem cell 2mg/mL 2μg/mL 
Hygromycin Mouse embryonic stem cell 200mg/mL 200μg/mL 




Supplementary table 3. Embryonic stem cell medium (ESM) formula. 
Embryonic Stem Cell Medium (ESM) Formula 
Material Per 250 mL Per 500 mL 
Dulbecco’s modified Eagle’s medium (DMEM) 
High glucose, pyruvate, Gibco, 11995-065 
215 mL 516 mL 
Fetal Bovine Serum (FBS) 
Moregate Biotech FBS sterile filtered, MG-FBSF-500ML 
37.5 mL 90 mL 
Penicillin-Streptomycin  
1,00x, Life Tech, 15140-122 
2.5 mL 6 mL 
MEM Non-Essential Amino Acids Solution 
1,00x, Life Tech, 1140-050 
2.5 mL 6 mL 
2-Mercaptoethanol  
55mM, Life Tech, 21985-023 
250 μL 600 μL 
Leukæmia Inhibitory Factor (LIF) 10 μg/ mL  
1,000x, diluted in PBS + 0.1% bovine serum albumin (BSA), sourced from 
CSCR Sally Lees 
250 μL 500 μL 
 
 
Supplementary table 4. Volume of different reagents used for various cell culture plate sizes. 
Dish Size Media Volume Accutase® PBS Wash Gelatine 
96-well Plate 200μL/ well 30-50μL/ well 140μL/ well 100μL/ well 
24-well Plate 1mL/ well 200μL/ well 700μL/ well 400μL/ well 
12-well Plate 2mL/ well 300μL/ well 1.4mL/ well 600μL/ well 
6-well Plate 3-4mL/ well 400μL/ well 2.7mL/ well 800μL/ well 
6cm Dish 6mL 600 μL 4.2mL 1.2mL 
10cm Dish 10mL 1mL 7mL 2mL 
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Supplementary table 5.  V6.5 TET variant transfected PBAT sample primer configuration 




















B1 A2 D3 B8 
C1 A3 E3 B9 
D1 A4 F3 B10 
E1 A5 G3 B11 
F1 A6 H3 B12 
G1 A7 A4 C1 
H1 A8 B4 C2 
A2 A9 C4 C3 
B2 A10 D4 C4 
C2 A11 E4 C5 
D2 A12 F4 C6 
E2 B1 H4 C7 
F2 B2 B5 C8 
G2 B3 D5 C9 
H2 B4 E5 C10 
A3 B5 F5 C11 
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Supplementary table 6. E14 TET variant transfected PBAT sample primer configuration 




















B1 A2 D3 B8 
C1 A3 E3 B9 
D1 A4 F3 B10 
E1 A5 G3 B11 
F1 A6 H3 B12 
G1 A7 A4 C1 
H1 A8 B4 C2 
A2 A9 C4 C3 
B2 A10 D4 C4 
C2 A11 E4 C5 
D2 A12 F4 C6 
E2 B1 E5 C7 
F2 B2 F5 C8 
G2 B3 G5 C9 
H2 B4   
A3 B5   
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Supplementary table 7. E14 & V6.5 CMT3 transfection bisulphite sequencing result 
Sample Name Total Reads Methylated Calls Methylation Percentage 
GC Methylation 
E14 mCherry Positive I 3,353 2,425 72.3% 
E14 Control I 1,043 727 69.7% 
E14 mCherry Positive II 2,597 1,969 75.8% 
E14 Control II 365 254 69.6% 
E14 mCherry Positive III 2,624 2,011 76.6% 
E14 Control III 716 452 63.1% 
V6.5 mCherry Positive I 924 651 70.5% 
V6.5 Control I 2,645 1,838 69.9% 
V6.5 mCherry Positive II 608 458 75.3% 
V6.5 Control II 3,285 2,300 70.0% 
V6.5 mCherry Positive III 578 442 76.5% 
CHG Methylation 
E14 mCherry Positive I 14,562 178 1.2% 
E14 Control I 4,885 46 0.9% 
E14 mCherry Positive II 12,369 166 1.3% 
E14 Control II 1,870 15 0.8% 
E14 mCherry Positive III 12,747 159 1.2% 
E14 Control III 3,459 46 1.3% 
V6.5 mCherry Positive I 4,071 75 1.8% 
V6.5 Control I 12,772 250 2.0% 
V6.5 mCherry Positive II 2,902 39 1.3% 
V6.5 Control II 14,552 237 1.6% 
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Sample Name Total Reads Methylated Calls Methylation Percentage 
V6.5 mCherry Positive III 3,159 53 1.7% 
CHH Methylation  
E14 mCherry Positive I 44,633 462 1.0% 
E14 Control I 15,688 140 0.9% 
E14 mCherry Positive II 41,058 342 0.8% 
E14 Control II 6,320 41 0.6% 
E14 mCherry Positive III 41,492 432 1.0% 
E14 Control III 11,365 97 0.9% 
V6.5 mCherry Positive I 13,075 179 1.4% 
V6.5 Control I 40,076 598 1.5% 
V6.5 mCherry Positive II 9,242 103 1.1% 
V6.5 Control II 47,026 615 1.3% 
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Supplementary table 8. CMT3 DNMT-TKO bisulphite sequencing result. 
Sample name  Total Reads Methylated reads Methylation percentage 
CG Methylation  
DNMT-TKO I  25,807 164 0.64% 
DNMT-TKO II 27,813 172 0.62% 
DNMT-TKO III 24,233 155 0.64% 
CHH Methylation 
DNMT-TKO I 108,234 619 0.57% 
DNMT-TKO II 122,106 669 0.55% 
DNMT-TKO III 104,930 496 0.47% 
CHH Methylation 
DNMT-TKO I  318,519 1,410 0.44% 
DNMT-TKO II 364,410 1,728 0.47% 
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Supplementary table 9. TET variants V6.5 bisulphite sequencing result 
Sample name  Total read Methylated reads Methylation percentage 
V6.5 Cherry I Neg 6,502 4,644 71.4% 
V6.5 Cherry II Neg 1,488 922 62.0% 
V6.5 Cherry III Neg 5,895 4,177 70.9% 
V6.5 Control I Neg 4,820 3,427 71.1% 
V6.5 Control II Neg 1,207 846 70.1% 
V6.5 Control III Neg 7,192 4,948 68.8% 
V6.5 mTET1-CD I Cherry 9,184 4,883 53.2% 
V6.5 mTET1-CD I Neg 3,500 2,068 59.1% 
V6.5 mTET1-CD II Cherry 8,295 4,843 58.4% 
V6.5 mTET1-CD II Neg 6,212 3,818 61.5% 
V6.5 mTET1-CD III Cherry 6,572 3,669 55.8% 
V6.5 mTET1-CD III Neg 9,812 6,156 62.7% 
V6.5 nTET A212N I Cherry 1,986 1,557 78.4% 
V6.5 nTET A212N I Neg 1,432 990 69.1% 
V6.5 nTET A212N II Cherry 1,121 866 77.3% 
V6.5 nTET A212N II Neg 1,385 972 70.2% 
V6.5 nTET A212N III Cherry 2,932 2,223 75.8% 
V6.5 nTET A212N III Neg 1,046 653 62.4% 
V6.5 nTET A212T I Cherry 4,866 3,680 75.6% 
V6.5 nTET A212T I Neg 3,990 2,636 66.1% 
V6.5 nTET A212T II Cherry 5,684 4,133 72.7% 
V6.5 nTET A212T II Neg 295 215 72.9% 
V6.5 nTET A212T III Cherry 2,095 1,551 74.0% 
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Sample name  Total read Methylated reads Methylation percentage 
V6.5 nTET A212T III Neg 4,065 2,827 69.5% 
V6.5 nTET A212V I Cherry 7,236 5,573 77.0% 
V6.5 nTET A212V I Neg 4,873 3,199 65.6% 
V6.5 nTET A212V II Cherry 4,856 3,648 75.1% 
V6.5 nTET A212V II Neg 3,923 2,613 66.6% 
V6.5 nTET A212V III Cherry 9,239 7,202 78.0% 
V6.5 nTET A212V III Neg 3,744 2,438 65.1% 
V6.5 nTET template I Cherry 9,699 6,112 63.0% 
V6.5 nTET template I  323 201 62.2% 
V6.5 nTET template II Cherry 586 422 72.0% 
V6.5 nTET template II Neg 2,383 1,574 66.1% 
V6.5 nTET template III Cherry 5,013 3,812 76.0% 
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Supplementary table 10.TET variants E14 bisulphite sequencing result. 
Sample name Total reads Methylated Reads Methylation percentage 
E14-Control I Neg 2,748 1,613 58.7% 
E14-Control II Neg 7424 4,462 60.10% 
E14 Control III Neg 12,764 7,178 56.2% 
E14 mTET1-CD I Cherry 132 64 48.5% 
E14 mTET1-CD I Neg 2,552 1,586 62.1% 
E14 mTET1-CD II Cherry 4,143 2,225 53.7% 
E14 mTET1-CD II Neg 3,003 1,794 59.7% 
E14 mTET1-CD III Cherry 5,006 2,490 49.7% 
E14 mTET1-CD III Neg 4,315 2,738 63.5% 
E14 nTET A212N I Cherry 2684 1,391 51.8% 
E14 nTET A212N I Neg 3229 1,661 51.4% 
E14 nTET A212N II Cherry 3097 1,660 53.6% 
E14 nTET A212N II Neg 4132 2170 52.5% 
E14-nTET-A212N III Cherry 1,510 802 53.1% 
E14 nTET A212N III Neg 4,666 2,574 55.2% 
E14 nTET A212T I Cherry 3,524 2,005 56.9% 
E14-nTET-A212T-I-Neg_S50 4,370 2,444 55.9% 
E14 nTET A212T II Cherry 9,522 5,264 55.3% 
E14 nTET A212T II Neg 6,111 3,472 56.8% 
E14 nTET A212T III Cherry 13,008 7,321 56.3% 
E14 nTET A212T III Neg 4,282 2,466 57.6% 
E14 nTET A212V I Cherry 7,081 4,379 61.8% 
E14 nTET A212V I Neg 2,283 1,324 58.0% 
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Sample name Total reads Methylated Reads Methylation percentage 
E14 nTET A212V II Cherry 5,444 3,334 61.2% 
E14 nTET A212V II Neg 3,194 48,113 59.9% 
E14 nTET A212V III Cherry 2,869 1,913 61.7% 
E14 nTET A212V III Neg 9,479 1,770 58.9% 
E14 nTET template I Cherry 2,405 5,587 67.2% 
E14 nTET template I Neg 4,451 1,615 55.7% 
E14 nTET template II Cherry 5,217 2,481 60.6% 
E14 nTET template II Neg 3,088 3,162 60.0% 
E14 nTET template III Cherry 12,824 1,852 60.9% 
E14 nTET template III Neg 4,689 7,814 57.8% 
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